T. Rowe Price Health Sciences Fund (PRHSX) N-CSR Certified annual shareholder report (management investment company)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-CSR

CERTIFIED SHAREHOLDER REPORT OF REGISTERED

MANAGEMENT INVESTMENT COMPANIES

Investment Company Act File Number: 811-07381

T. Rowe Price Health Sciences Fund, Inc.

(Exact name of registrant as specified in charter)

100 East Pratt Street, Baltimore, MD 21202

(Address of principal executive offices)

David Oestreicher

100 East Pratt Street, Baltimore, MD 21202

(Name and address of agent for service)

Registrant’s telephone number, including area code: (410) 345-2000

Date of fiscal year end: December 31

Date of reporting period: December 31, 2022

Item 1. Reports to Shareholders

(a) Report pursuant to Rule 30e-1

Highlights

and

Market

Commentary

Management’s

Discussion

of

Fund

Performance

Performance

and

Expenses

Financial

Highlights

Portfolio

of

Investments

Financial

Statements

and

Notes

Additional

Fund

Information

December

31,

2022

Annual

Report

For

more

insights

from

T.

Rowe

Price

investment

professionals,

go

to

troweprice.com

.

T.

ROWE

PRICE

PRHSX

Health

Sciences

Fund

–

.

THISX

Health

Sciences

Fund–

.

I Class

T.

ROWE

PRICE

Health

Sciences

Fund

HIGHLIGHTS

The

Health

Sciences

Fund

outperformed

its

benchmark

and

the

broad

equity

market

in

the

12

months

ended

December

31,

2022.

Allocation

effects

drove

outperformance,

while

stock

selection

detracted.

The

services

and

pharmaceuticals

subsectors

contributed

the

most

to

relative

performance,

while

biotechnology

and

life

sciences

detracted.

While

we

expect

the

macroeconomic

backdrop

to

remain

challenging

in

the

near

term,

we

maintain

an

optimistic

outlook

for

the

sector

going

forward.

We

believe

investors

need

to

be

selective,

and

we

are

staying

true

to

our

philosophy

of

investing

in

highly

innovative

therapeutic

companies

and

companies

that

can

improve

the

standard

of

care

in

a

cost-effective

manner,

which

has

served

us

well

over

time.

Log

in

to

your

account

at

troweprice.com

for

more

information.

*

Certain

mutual

fund

accounts

that

are

assessed

an

annual

account

service

fee

can

also

save

money

by

switching

to

e-delivery.

T.

ROWE

PRICE

Health

Sciences

Fund

Market

Commentary

1

Dear

Shareholder

Nearly

all

major

global

stock

and

bond

indexes

fell

sharply

in

2022,

as

investors

contended

with

persistently

high

inflation,

tightening

financial

conditions,

and

slowing

economic

and

corporate

earnings

growth.

Double-digit

losses

were

common

in

equity

markets

around

the

world,

and

bond

investors

also

faced

a

historically

tough

environment

amid

a

sharp

rise

in

interest

rates.

Value

shares

declined

but

outperformed

growth

stocks

by

a

considerable

margin

as

equity

investors

turned

risk

averse

and

as

rising

rates

put

downward

pressure

on

growth

stock

valuations.

Emerging

markets

stocks

generally

underperformed

shares

in

developed

markets.

Meanwhile,

the

U.S.

dollar

strengthened

versus

most

currencies

during

the

period,

which

weighed

on

returns

for

U.S.

investors

in

international

securities.

Within

the

S&P

500

Index,

energy

was

a

rare

bright

spot,

gaining

more

than

60%

as

oil

prices

jumped

in

response

to

Russia’s

invasion

of

Ukraine

and

concerns

over

commodity

supply

shortages.

Defensive

shares,

such

as

utilities,

consumer

staples,

and

health

care,

held

up

relatively

well

and

finished

the

year

with

roughly

flat

returns.

Conversely,

communication

services,

consumer

discretionary,

and

information

technology

shares

suffered

the

largest

declines.

Elevated

inflation

remained

a

leading

concern

for

investors

throughout

the

period,

although

there

were

signs

that

price

increases

were

moderating

by

year-

end.

November’s

consumer

price

index

data

showed

headline

inflation

rising

7.1%

on

a

12-month

basis,

the

lowest

level

since

December

2021

but

still

well

above

the

Federal

Reserve’s

2%

long-term

target.

In

response

to

the

high

inflation

readings,

global

central

banks

tightened

monetary

policy,

and

investors

focused

on

communications

from

central

bank

officials

on

how

high

rates

would

have

to

go.

The

Fed,

which

at

the

end

of

2021

had

forecast

that

it

would

only

need

to

raise

interest

rates

0.75

percentage

point

in

all

of

2022,

raised

its

short-term

lending

benchmark

from

near

zero

in

March

to

a

target

range

of

4.25%

to

4.50%

by

December

and

indicated

that

additional

hikes

are

likely.

Bond

yields

increased

considerably

across

the

U.S.

Treasury

yield

curve

as

the

Fed

tightened

monetary

policy,

with

the

yield

on

the

benchmark

10-year

U.S.

Treasury

note

climbing

from

1.52%

at

the

start

of

the

period

to

3.88%

at

the

end

of

the

year.

Significant

inversions

in

the

yield

curve,

which

are

often

considered

a

warning

sign

of

a

coming

recession,

occurred

during

the

period

as

shorter-maturity

Treasuries

experienced

the

largest

yield

increases.

The

T.

ROWE

PRICE

Health

Sciences

Fund

2

sharp

increase

in

yields

led

to

historically

weak

results

across

the

fixed

income

market,

with

the

Bloomberg

U.S.

Aggregate

Bond

Index

delivering

its

worst

year

on

record.

(Bond

prices

and

yields

move

in

opposite

directions.)

As

the

period

came

to

an

end,

the

economic

backdrop

appeared

mixed.

Although

manufacturing

gauges

have

drifted

toward

contraction

levels,

the

U.S.

jobs

market

remained

resilient,

and

corporate

and

household

balance

sheets

appeared

strong.

Meanwhile,

the

housing

market

has

weakened

amid

rising

mortgage

rates.

The

past

year

has

been

a

trying

time

for

investors

as

few

sectors

remained

untouched

by

the

broad

headwinds

that

markets

faced,

and

volatility

may

continue

in

the

near

term

as

central

banks

tighten

policy

amid

slowing

economic

growth.

However,

in

our

view,

there

continue

to

be

opportunities

for

selective

investors

focused

on

fundamentals.

Valuations

in

most

global

equity

markets

have

improved

markedly,

although

U.S.

equities

still

appear

relatively

expensive

by

historical

standards,

while

bond

yields

have

reached

some

of

the

most

attractive

levels

since

the

2008

global

financial

crisis.

We

believe

this

environment

makes

skilled

active

management

a

critical

tool

for

identifying

risks

and

opportunities,

and

our

investment

teams

will

continue

to

use

fundamental

research

to

identify

securities

that

can

add

value

to

your

portfolio

over

the

long

term.

Thank

you

for

your

continued

confidence

in

T.

Rowe

Price.

Sincerely, 

Robert

Sharps

CEO

and

President

T.

ROWE

PRICE

Health

Sciences

Fund

Management’s

Discussion

of

Fund

Performance

3

INVESTMENT

OBJECTIVE 

The

fund

seeks

long-term

capital

appreciation.

FUND

COMMENTARY

How

did

the

fund

perform

in

the

past 12

months?

The

Health

Sciences

Fund

returned

-12.19%

in

the

12-month

period

ended

December

31,

2022.

The

fund

outperformed

its

benchmark,

the

Lipper

Health/

Biotechnology

Funds

Index,

and

the

broad

equity

market

as

measured

by

the

S&P

500

Index.

(Returns

for

I

Class

shares

varied

slightly,

reflecting

their

different

fee

structure.

Past

performance

cannot

guarantee

future

results

.)

What

factors

influenced

the

fund’s

performance?

Allocation

effects

drove

outperformance,

while

stock

selection

detracted.

However,

we

believe

our

focus

on

bottom-up

stock

selection

will

be

the

primary

long-term

performance

driver

as

shown

in

the

Growth

of

$10,000

chart

on

page

9.

The

portfolio’s

overweight

exposure

to

services

contributed

the

most

to

relative

returns;

stock

choices

in

the

group

also

assisted.

Select

managed

care

names

such

as

UnitedHealth

Group

and

Elevance

Health

added

value.

The

group

benefited

from

strong

fundamentals

driven

by

a

robust

commercial

pricing

environment,

broadly

in-line

health

care

utilization

trends,

and

abating

political

overhangs.

Additionally,

these

are

largely

U.S.

domestic-oriented

businesses

with

strong

cash

flows

that

have

demonstrated

the

ability

to

adjust

price

and/or

benefits

in

response

to

cost

inflation,

which

investors

have

appreciated.

An

overweight

exposure

to

larger-cap

pharmaceuticals,

which

benefited

from

their

more

defensive

characteristics,

was

another

source

of

relative

strength.

Investors’

preference

for

companies

with

strong

balance

sheets

and

cash

flow

generation

in

an

environment

with

persistent

inflation

and

rising

interest

rates

benefited

firms

such

as

Merck

and

Eli

Lilly.

PERFORMANCE

COMPARISON

Total

Return

Periods

Ended

12/31/22

6

Months

12

Months

Health

Sciences

Fund

–

.

6.60‌%

-12.19‌%

Health

Sciences

Fund–

.

I  Class

6.67‌

-12.08‌

S&P

500

Index

2.31‌

-18.11‌

Lipper

Health/

Biotechnology

Funds

Index

10.33‌

-12.94‌

T.

ROWE

PRICE

Health

Sciences

Fund

4

Conversely,

stock

picks

in

the

biotechnology

subsector

detracted.

The

portfolio’s

underweight

position

in

several

names

that

outperformed

during

the

year,

mainly

due

to

positive

data

readouts,

weighed

on

relative

returns.

Shares

of

Karuna

Therapeutics

traded

sharply

higher

following

a

positive

Phase

3

data

readout

for

its

potential

schizophrenia

treatment

in

early

August,

which

significantly

improved

the

drug’s

chances

of

approval

by

the

U.S.

Food

and

Drug

Administration.

Although

we

added

to

our

position

in

Karuna

before

and

after

the

data

readout,

our

underweight

allocation

hurt

performance.

While

a

leadership-change

announcement

in

early

December

weighed

on

the

stock

more

recently,

we

remain

constructive

on

the

company

as

we

believe

there

is

a

significant

amount

of

upside

to

be

captured

in

its

paradigm-shifting

therapy

for

schizophrenia.

An

overweight

exposure

to

life

sciences,

the

worst-performing

segment

in

the

benchmark

during

the

year,

also

lowered

relative

returns;

however,

stock

selection

in

the

group

helped

mitigate

losses.

Growing

concerns

of

a

slowdown

in

COVID-19

vaccine-related

demand

weighed

on

larger

companies

with

bioprocessing

exposure

within

the

sector,

while

smaller-cap,

more

capital-

intensive

companies

were

hurt

by

rapidly

rising

interest

rates.

However,

we

think

the

longer-term

outlook

for

the

group

remains

favorable,

supported

by

the

ongoing

innovation

in

biopharma.

How

is

the

fund

positioned?

From

a

high

level,

the

areas

that

we

have

always

favored

(companies

developing

innovative,

game-changing

therapies

and

companies

that

are

improving

the

standard

of

care

in

a

cost-effective

manner)

will

remain

areas

we

focus

on

because

that

is

where

we

think

investors

can

realize

long-term

value.

From

a

subsector

perspective,

biotechnology

represents

the

portfolio’s

largest

exposure.

While

we

remain

committed

to

investing

in

innovative

companies

developing

new

medicines,

we

recognize

the

environment

for

smaller

biotechnology

companies

has

changed,

as

raising

capital

has

become

more

difficult.

As

such,

we

have

set

a

higher

bar

for

owning

nonprofitable

INDUSTRY

DIVERSIFICATION

Percent

of

Net

Assets

6/30/22

12/31/22

Biotechnology

25.2‌%

26.8‌%

Services

24.3‌

23.6‌

Pharmaceuticals

17.3‌

18.0‌

Life

Sciences

15.8‌

15.9‌

Products

and

Devices

16.6‌

14.7‌

Consumer

Nondurables

0.6‌

0.2‌

Other

and

Reserves

0.2‌

0.8‌

Total

100.0‌%

100.0‌%

Historical

weightings

reflect

current

industry/sector

classifications.

T.

ROWE

PRICE

Health

Sciences

Fund

5

biotechnology

companies.

Conversely,

we

have

found

opportunities

to

selectively

add

to

larger-cap

biotechnology

companies

with

strong

research

and

development

capabilities

that

are

profitable

and

fairly

valued

given

the

likelihood

that

higher

interest

rates

and

higher

inflation

will

remain

for

longer

than

many

expect.

We

added

to

our

position

in

Regeneron

Pharmaceuticals,

a

commercial-stage

biotechnology

company

focused

on

the

development

and

commercialization

of

biologic

drugs.

We

believe

the

recent

success

of

two

Phase

3

trials

for

high-

dose

Eylea,

an

injection

indicated

to

treat

a

variety

of

ocular

diseases,

was

a

significant

step

in

the

life-cycle

management

of

the

company’s

blockbuster

drug.

We

think

the

positive

readouts

substantially

extend

the

revenue

runway

for

the

company,

and

we

believe

the

valuation

remains

favorable

given

its

now-durable

growth

profile.

Conversely,

we

eliminated

our

position

in

Amgen

on

strength

during

the

second

quarter.

While

the

company

has

a

growing

dividend,

solid

cash

flow

generation,

and

a

strong

internal

research

and

development

program,

the

stock

had

become

more

fairly

valued

in

our

view,

due

to

investor

interest

in

companies

with

pharma-like

profiles,

and

we

elected

to

take

profits

and

fund

other

higher-conviction

ideas.

With

limited

inflation

and

input

cost

pressures

as

well

as

strong

balance

sheets

and

cash

flow

generation,

larger-cap

pharmaceuticals

have

benefited

from

their

more

defensive

characteristics.

Given

rising

recession

uncertainties

and

the

diminished

investor

appetite

for

risk-taking,

we

have

modestly

increased

our

exposure

to

the

group.

We

added

shares

of

Merck,

which

we

believe

should

be

able

to

drive

revenue

growth

in

the

medium

term

with

its

human

papillomavirus

vaccine

Gardasil,

its

oncology

treatments

Lenvima

and

Lynparza,

as

well

as

its

animal

health

business.

Merck

may

also

be

able

to

utilize

its

strong

balance

sheet

and

cash

flows

to

finance

significant

acquisitions

and

bolster

its

pipeline.

Conversely,

we

scaled

back

our

position

in

Pfizer

as

the

stock’s

near-term

outlook

is

heavily

tied

to

its

COVID

portfolio,

which

remains

difficult

to

forecast.

Within

the

services

subsector,

our

largest

exposure

is

to

the

structurally

growing

managed

care

industry,

where

fundamentals

remain

strong

given

a

favorable

commercial

pricing

environment.

Within

the

space,

we

have

significant

positions

in

UnitedHealth

Group,

Humana,

and

Elevance

Health.

Regarding

Elevance,

which

was

our

largest

addition

in

the

subsector

during

the

period,

we

think

it

offers

an

attractive

mix

of

company-specific

growth

drivers

at

a

compelling

valuation

when

considering

the

company’s

room

for

improving

returns

and

long

runway

for

growth

with

its

Medicaid

and

Medicare

Advantage

businesses.

T.

ROWE

PRICE

Health

Sciences

Fund

6

The

portfolio

is

overweight

life

sciences

companies,

which

develop

the

platforms,

instrumentation,

and

technology

that

drives

future

discovery

and

the

application

of

drugs

and

diagnostics.

Fundamentals

overall

remain

exceptional.

Within

the

space,

we

have

core

positions

in

Thermo

Fisher

Scientific,

Danaher,

and

Agilent

Technologies.

What

is

portfolio

management’s

outlook?

Macroeconomic

factors

dominated

equity

market

performance

in

2022,

with

higher

interest

rates,

rising

inflation,

and

growing

recessionary

fears

weighing

on

investor

confidence.

While

we

expect

the

macroeconomic

backdrop

to

remain

challenging

in

the

near

term,

we

maintain

an

optimistic

outlook

for

the

sector

going

forward.

We

are

seeing

great

progress

across

a

number

of

therapeutic

platforms,

including

oncology,

neurology,

ophthalmology,

and

autoimmune

and

infectious

diseases,

and

the

market

environment

for

companies

developing

innovative

therapies

remains

encouraging.

Even

with

the

groundbreaking

developments

we

have

seen

over

the

last

several

years,

there

is

still

a

strong

pipeline

for

future

innovation

given

the

large

number

of

disorders,

such

as

cancer,

Alzheimer’s,

obesity,

and

diabetes,

affecting

large

populations

in

need

of

improved

treatment

options.

As

a

result

of

ongoing

scientific

advancement

and

improvement,

we

believe

we

are

on

the

cusp

of

a

significant

wave

of

innovation

that

should

lead

to

meaningful

drug

launches

in

the

coming

years

that

will

cure

diseases

or

dramatically

improve

quality

of

life.

Encouragingly,

innovation

is

occurring

in

companies

of

all

sizes,

and

we

continue

to

own

a

well-diversified

portfolio

of

names

across

the

health

care

landscape.

Although

we

believe

investors

must

remain

selective

amid

this

period

of

near-term

uncertainty,

we

are

staying

true

to

our

investment

philosophy

and

process.

The

views

expressed

reflect

the

opinions

of

T.

Rowe

Price

as

of

the

date

of

this

report

and

are

subject

to

change

based

on

changes

in

market,

economic,

or

other

conditions.

These

views

are

not

intended

to

be

a

forecast

of

future

events

and

are

no

guarantee

of

future

results.

T.

ROWE

PRICE

Health

Sciences

Fund

7

RISKS

OF

GROWTH

INVESTING

Growth

stocks

can

be

volatile

for

several

reasons.

Since

these

companies

usually

invest

a

high

portion

of

earnings

in

their

businesses,

they

may

lack

the

dividends

of

value

stocks

that

can

cushion

stock

prices

in

a

falling

market.

Also,

earnings

disappointments

often

lead

to

sharply

falling

prices

because

investors

buy

growth

stocks

in

anticipation

of

superior

earnings

growth.

RISKS

OF

HEALTH

SCIENCES

FUND

INVESTING

Funds

that

invest

only

in

specific

industries

will

experience

greater

volatility

than

funds

investing

in

a

broad

range

of

industries.

Companies

in

the

health

sciences

field

are

subject

to

special

risks

such

as

increased

competition

within

the

health

care

industry,

changes

in

legislation

or

government

regulations,

reductions

in

government

funding,

product

liability

or

other

litigation,

and

the

obsolescence

of

popular

products.

BENCHMARK

INFORMATION

Note:

Portions

of

the

mutual

fund

information

contained

in

this

report

was

supplied

by

Lipper,

a

Refinitiv

Company,

subject

to

the

following:

Copyright

2023

©

Refinitiv.

All

rights

reserved.

Any

copying,

republication

or

redistribution

of

Lipper

content

is

expressly

prohibited

without

the

prior

written

consent

of

Lipper.

Lipper

shall

not

be

liable

for

any

errors

or

delays

in

the

content,

or

for

any

actions

taken

in

reliance

thereon.

Note:

The

S&P

500

Index

is

a

product

of

S&P

Dow

Jones

Indices

LLC,

a

division

of

S&P

Global,

or

its

affiliates

(“SPDJI”)

and

has

been

licensed

for

use

by

T.

Rowe

Price.

Standard

&  Poor’s

®

and

S&P

®

 are

registered

trademarks of

Standard

&

Poor’s

Financial

Services

LLC,

a

division

of

S&P

Global (“S&P”);

Dow

Jones

®

is

a

registered

trademark

of

Dow

Jones

Trademark

Holdings

LLC

(“Dow

Jones”);

T.

Rowe

Price

is

not

sponsored,

endorsed,

sold

or

promoted

by

SPDJI,

Dow

Jones,

S&P,

or

their

respective

affiliates,

and

none

of

such

parties

make

any

representation

regarding

the

advisability

of

investing

in

such

product(s)

nor

do

they

have

any

liability

for

any

errors,

omissions,

or

interruptions

of

the

S&P

500

Index.

T.

ROWE

PRICE

Health

Sciences

Fund

8

PORTFOLIO

HIGHLIGHTS

TWENTY-FIVE

LARGEST

HOLDINGS

Percent

of

Net

Assets

12/31/22

UnitedHealth

Group

8.7‌%

Thermo

Fisher

Scientific

5.1‌ 

Eli

Lilly

4.5‌ 

Danaher

3.8‌ 

Merck

3.5‌ 

AstraZeneca

3.4‌ 

Elevance

Health

3.2‌ 

Regeneron

Pharmaceuticals

3.0‌ 

Intuitive

Surgical

3.0‌ 

Stryker

2.3‌ 

Pfizer

2.3‌ 

Alnylam

Pharmaceuticals

2.3‌ 

Vertex

Pharmaceuticals

2.2‌ 

Humana

2.2‌ 

Agilent

Technologies

2.0‌ 

Becton

Dickinson

&

Company

1.8‌ 

AbbVie

1.7‌ 

Centene

1.7‌ 

Argenx

1.7‌ 

Molina

Healthcare

1.6‌ 

Cigna

1.5‌ 

Moderna

1.2‌ 

Penumbra

0.9‌ 

Hologic

0.9‌ 

HCA

Healthcare

0.9‌ 

Total

65.4‌%

Note:

The

information

shown

does

not

reflect

any

exchange-traded

funds

(ETFs),

cash

reserves,

or

collateral

for

securities

lending

that

may

be

held

in

the

portfolio.

T.

ROWE

PRICE

Health

Sciences

Fund

9

GROWTH

OF

$10,000 

This

chart

shows

the

value

of

a

hypothetical

$10,000

investment

in

the

fund

over

the

past

10

fiscal

year

periods

or

since

inception

(for funds

lacking

10-year

records).

The

result

is

compared

with

benchmarks,

which

include

a

broad-based

market

index

and

may

also

include

a

peer

group

average

or

index.

Market

indexes

do

not

include

expenses,

which

are

deducted

from

fund returns

as

well

as

mutual fund

averages

and

indexes.

HEALTH

SCIENCES

FUND 

Note:

Performance

for

the

I

Class share

will

vary

due

to

its differing

fee

structure.

See

the

Average

Annual

Compound

Total

Return

table. 

T.

ROWE

PRICE

Health

Sciences

Fund

10

AVERAGE

ANNUAL

COMPOUND

TOTAL

RETURN

Periods

Ended

12/31/22

1

Year

5

Years

10

Years

Since

Inception

Inception

Date

Health

Sciences

Fund

–

.

-12.19‌%

11.08‌%

15.91‌%

–‌

–

Health

Sciences

Fund–

.

I  Class

-12.08‌

11.21‌

–‌

12.77‌%

3/23/16

The

fund’s

performance

information

represents

only

past

performance

and

is

not

necessarily

an

indication

of

future

results.

Current

performance

may

be

lower

or

higher

than

the

performance

data

cited.

Share

price,

principal

value,

and

return

will

vary,

and

you

may

have

a

gain

or

loss

when

you

sell

your

shares.

For

the

most

recent

month-end

performance,

please

visit

our

website

(troweprice.com)

or

contact

a

T.

Rowe

Price

representative

at

1

-

800

-

225

-

5132

or,

for

0.02

I

Class

shares,

1-800-638-8790.

This

table

shows

how

the

fund

would

have

performed

each

year

if

its

actual

(or

cumulative)

returns

had

been

earned

at

a

constant

rate.

Average

annual

total

return

figures

include

changes

in

principal

value,

reinvested

dividends,

and

capital

gain

distributions.

Returns

do

not

reflect

taxes

that

the

shareholder

may

pay

on

fund

distributions

or

the

redemption

of

fund

shares.

When

assessing

performance,

investors

should

consider

both

short-

and

long-term

returns.

T.

ROWE

PRICE

Health

Sciences

Fund

11

EXPENSE

RATIO

FUND

EXPENSE

EXAMPLE

As

a

mutual

fund

shareholder,

you

may

incur

two

types

of

costs:

(1)

transaction

costs,

such

as

redemption

fees

or

sales

loads,

and

(2)

ongoing

costs,

including

management

fees,

distribution

and

service

(12b-1)

fees,

and

other

fund

expenses.

The

following

example

is

intended

to

help

you

understand

your

ongoing

costs

(in

dollars)

of

investing

in

the

fund

and

to

compare

these

costs

with

the

ongoing

costs

of

investing

in

other

mutual

funds.

The

example

is

based

on

an

investment

of

$1,000

invested

at

the

beginning

of

the

most

recent

six-month

period

and

held

for

the

entire

period.

Please

note

that

the

fund

has

two

share

classes:

The

original

share

class

(Investor

Class)

charges

no

distribution

and

service

(12b-1)

fee,

and

the

I

Class

shares

are

also

available

to

institutionally

oriented

clients

and

impose

no

12b-1

or

administrative

fee

payment.

Each

share

class

is

presented

separately

in

the

table.

Actual

Expenses

The

first

line

of

the

following

table

(Actual)

provides

information

about

actual

account

values

and

expenses

based

on

the

fund’s

actual

returns.

You

may

use

the

information

on

this

line,

together

with

your

account

balance,

to

estimate

the

expenses

that

you

paid

over

the

period.

Simply

divide

your

account

value

by

$1,000

(for

example,

an

$8,600

account

value

divided

by

$1,000

=

8.6),

then

multiply

the

result

by

the

number

on

the

first

line

under

the

heading

“Expenses

Paid

During

Period”

to

estimate

the

expenses

you

paid

on

your

account

during

this

period.

Hypothetical

Example

for

Comparison

Purposes

The

information

on

the

second

line

of

the

table

(Hypothetical)

is

based

on

hypothetical

account

values

and

expenses

derived

from

the

fund’s

actual

expense

ratio

and

an

assumed

5%

per

year

rate

of

return

before

expenses

(not

the

fund’s

actual

return).

You

may

compare

the

ongoing

costs

of

investing

in

the

fund

with

other

funds

by

contrasting

this

5%

hypothetical

example

and

the

5%

hypothetical

examples

that

appear

in

the

shareholder

reports

of

the

other

funds.

The

hypothetical

account

values

and

expenses

may

not

be

used

to

estimate

the

actual

ending

account

balance

or

expenses

you

paid

for

the

period.

Health

Sciences

Fund

0.75‌%

Health

Sciences

Fund–I

Class

0.65‌ 

The

expense

ratio

shown

is

as

of

the

fund’s

most

recent

prospectus.

This

number

may

vary

from

the

expense

ratio

shown

elsewhere

in

this

report

because

it

is

based

on

a

different

time

period

and,

if

applicable,

includes

acquired

fund

fees

and

expenses

but

does

not

include

fee

or

expense

waivers.

T.

ROWE

PRICE

Health

Sciences

Fund

12

Note:

T.

Rowe

Price

charges

an

annual

account

service

fee

of

$20,

generally

for

accounts

with

less

than

$10,000.

The

fee

is

waived

for

any

investor

whose

T.

Rowe

Price

mutual

fund

accounts

total

$50,000

or

more;

accounts

electing

to

receive

electronic

delivery

of

account

statements,

transaction

confirmations,

prospectuses,

and

shareholder

reports;

or

accounts

of

an

investor

who

is

a

T.

Rowe

Price

Personal

Services

or

Enhanced

Personal

Services

client

(enrollment

in

these

programs

generally

requires

T.

Rowe

Price

assets

of

at

least

$250,000).

This

fee

is

not

included

in

the

accompanying

table.

If

you

are

subject

to

the

fee,

keep

it

in

mind

when

you

are

estimating

the

ongoing

expenses

of

investing

in

the

fund

and

when

comparing

the

expenses

of

this

fund

with

other

funds.

You

should

also

be

aware

that

the

expenses

shown

in

the

table

highlight

only

your

ongoing

costs

and

do

not

reflect

any

transaction

costs,

such

as

redemption

fees

or

sales

loads.

Therefore,

the

second

line

of

the

table

is

useful

in

comparing

ongoing

costs

only

and

will

not

help

you

determine

the

relative

total

costs

of

owning

different

funds.

To

the

extent

a

fund

charges

transaction

costs,

however,

the

total

cost

of

owning

that

fund

is

higher.

HEALTH

SCIENCES

FUND

Beginning

Account

Value

7/1/22

Ending

Account

Value

12/31/22

Expenses

Paid

During

Period*

7/1/22

to

12/31/22

Health

Sciences

Fund

Actual

$1,000.00

$1,066.00

$4.17

Hypothetical

(assumes

5%

return

before

expenses)

 1,000.00

  1,021.17

  4.08

Health

Sciences

Fund–I

Class

Actual

  1,000.00

  1,066.70

  3.49

Hypothetical

(assumes

5%

return

before

expenses)

 1,000.00

  1,021.83

  3.41

*

Expenses

are

equal

to

the

fund’s

annualized

expense

ratio

for

the

6-month

period,

multiplied

by

the

average

account

value

over

the

period,

multiplied

by

the

number

of

days

in

the

most

recent

fiscal

half

year

(184),

and

divided

by

the

days

in

the

year

(365)

to

reflect

the

half-year

period.

The

annualized

expense

ratio

of

the

1

Investor

Class

was

0.80%,

and

the

2

I Class

was

0.67%.

FUND

EXPENSE

EXAMPLE

(CONTINUED)

T.

ROWE

PRICE

Health

Sciences

Fund

Financial

Highlights

13

For

a

share

outstanding

throughout

each

period

Investor

Class

..

Year

..

..

Ended

.

12/31/22

12/31/21

12/31/20

12/31/19

12/31/18

NET

ASSET

VALUE

Beginning

of

period

$

104.08‌

$

98.85‌

$

81.43‌

$

67.01‌

$

70.35‌

Investment

activities

Net

investment

income

(loss)

(1)(2)

(0.09‌)

(0.22‌)

(0.04‌)

—‌

(3)

0.04‌

Net

realized

and

unrealized

gain/

loss

(12.58‌)

13.21‌

24.54‌

19.45‌

1.02‌

Total

from

investment

activities

(12.67‌)

12.99‌

24.50‌

19.45‌

1.06‌

Distributions

Net

investment

income

—‌

—‌

—‌

(0.05‌)

—‌

Net

realized

gain

(1.59‌)

(7.76‌)

(7.08‌)

(4.98‌)

(4.40‌)

Total

distributions

(1.59‌)

(7.76‌)

(7.08‌)

(5.03‌)

(4.40‌)

NET

ASSET

VALUE

End

of

period

$

89.82‌

$

104.08‌

$

98.85‌

$

81.43‌

$

67.01‌

T.

ROWE

PRICE

Health

Sciences

Fund

Financial

Highlights

14

For

a

share

outstanding

throughout

each

period

The

accompanying

notes

are

an

integral

part

of

these

financial

statements.

Investor

Class

..

Year

..

..

Ended

.

12/31/22

12/31/21

12/31/20

12/31/19

12/31/18

Ratios/Supplemental

Data

Total

return

(2)(4)

(12.19‌)%

13.27‌%

30.12‌%

29.11‌%

1.23‌%

Ratios

to

average

net

assets:

(2)

Gross

expenses

before

waivers/

payments

by

Price

Associates

0.80‌%

0.75‌%

0.76‌%

0.76‌%

0.77‌%

Net

expenses

after

waivers/

payments

by

Price

Associates

0.80‌%

0.75‌%

0.76‌%

0.76‌%

0.77‌%

Net

investment

income

(loss)

(0.10‌)%

(0.21‌)%

(0.05‌)%

0.00‌%

0.05‌%

Portfolio

turnover

rate

28.8‌%

33.8‌%

41.7‌%

38.8‌%

43.0‌%

Net

assets,

end

of

period

(in

millions)

$10,235

$17,213

$15,753

$12,649

$10,666

0‌%

0‌%

0‌%

0‌%

0‌%

(1)

Per

share

amounts

calculated

using

average

shares

outstanding

method.

(2)

See

Note

6

for

details

of

expense-related

arrangements

with

Price

Associates.

(3)

Amounts

round

to

less

than

$0.01

per

share.

(4)

Total

return

reflects

the

rate

that

an

investor

would

have

earned

on

an

investment

in

the

fund

during

each

period,

assuming

reinvestment

of

all

distributions,

and

payment

of

no

redemption

or

account

fees,

if

applicable.

T.

ROWE

PRICE

Health

Sciences

Fund

Financial

Highlights

15

For

a

share

outstanding

throughout

each

period

The

accompanying

notes

are

an

integral

part

of

these

financial

statements.

I

Class

..

Year

..

..

Ended

.

12/31/22

12/31/21

12/31/20

12/31/19

12/31/18

NET

ASSET

VALUE

Beginning

of

period

$

104.05‌

$

98.87‌

$

81.42‌

$

67.00‌

$

70.34‌

Investment

activities

Net

investment

income

(loss)

(1)(2)

0.05‌

(0.11‌)

0.05‌

0.08‌

0.14‌

Net

realized

and

unrealized

gain/

loss

(12.60‌)

13.22‌

24.57‌

19.46‌

1.01‌

Total

from

investment

activities

(12.55‌)

13.11‌

24.62‌

19.54‌

1.15‌

Distributions

Net

investment

income

—‌

—‌

—‌

(0.14‌)

—‌

Net

realized

gain

(1.59‌)

(7.93‌)

(7.17‌)

(4.98‌)

(4.49‌)

Total

distributions

(1.59‌)

(7.93‌)

(7.17‌)

(5.12‌)

(4.49‌)

NET

ASSET

VALUE

End

of

period

$

89.91‌

$

104.05‌

$

98.87‌

$

81.42‌

$

67.00‌

Ratios/Supplemental

Data

Total

return

(2)(3)

(12.08‌)%

13.40‌%

30.27‌%

29.25‌%

1.35‌%

Ratios

to

average

net

assets:

(2)

Gross

expenses

before

waivers/

payments

by

Price

Associates

0.67‌%

0.65‌%

0.65‌%

0.65‌%

0.66‌%

Net

expenses

after

waivers/

payments

by

Price

Associates

0.67‌%

0.65‌%

0.65‌%

0.65‌%

0.66‌%

Net

investment

income

(loss)

0.05‌%

(0.10‌)%

0.06‌%

0.11‌%

0.18‌%

Portfolio

turnover

rate

28.8‌%

33.8‌%

41.7‌%

38.8‌%

43.0‌%

Net

assets,

end

of

period

(in

thousands)

$5,937,842

$2,295,409

$1,679,405

$1,154,768

$835,422

0‌%

0‌%

0‌%

0‌%

0‌%

(1)

Per

share

amounts

calculated

using

average

shares

outstanding

method.

(2)

See

Note

6

for

details

of

expense-related

arrangements

with

Price

Associates.

(3)

Total

return

reflects

the

rate

that

an

investor

would

have

earned

on

an

investment

in

the

fund

during

each

period,

assuming

reinvestment

of

all

distributions,

and

payment

of

no

redemption

or

account

fees,

if

applicable.

T.

ROWE

PRICE

Health

Sciences

Fund

December

31,

2022

16

Portfolio

of

Investments

‡

Shares

$

Value

(Cost

and

value

in

$000s)

‡

COMMON

STOCKS

94.2%

BIOTECHNOLOGY

22.1%

International-Biotechnology

0.0%

Ideaya

Biosciences  (1)

134,265‌

2,440‌

2,440‌

Major

Biotechnology

4.9%

Biogen (1)

357,689‌

99,051‌

BioNTech,

ADR 

560,841‌

84,250‌

Celldex

Therapeutics  (1)

628,343‌

28,005‌

Exact

Sciences  (1)

952,069‌

47,137‌

Exact

Sciences

CMO

Milestone,

Acquisition

Date:

1/6/21,

Cost $—  (1)(2)(3)

3,726,272‌

1,975‌

Exact

Sciences

Expense

Fund,

Acquisition

Date:

1/6/21,

Cost $—  (1)(2)(3)

3,795‌

4‌

Exact

Sciences

FDA

Milestone,

Acquisition

Date:

1/6/21,

Cost $—  (1)(2)(3)

1,863,136‌

988‌

Neurocrine

Biosciences  (1)

343,178‌

40,989‌

Royalty

Pharma,

Class

A 

1,671,948‌

66,075‌

Seagen  (1)

463,072‌

59,509‌

Vertex

Pharmaceuticals  (1)

1,254,616‌

362,308‌

790,291‌

Other

Biotechnology

17.2%

Aadi

Bioscience  (1)

150,289‌

1,928‌

ACADIA

Pharmaceuticals  (1)

1,177,638‌

18,748‌

Acerta

Future

Payments,

EC,

Acquisition

Date:

6/30/21,

Cost $16,465  (1)(2)(3)

16,465,269‌

14,440‌

Adaptive

Biotechnologies  (1)

679,353‌

5,190‌

ADC

Therapeutics  (1)

1,173,088‌

4,505‌

Affinivax

Expense

Fund,

Acquisition

Date:

9/12/22,

Cost $12  (1)

(2)(3)

12,445‌

12‌

Affinivax

Milestone

Event,

Acquisition

Date:

9/12/22,

Cost $3,454  (1)(2)(3)

7,349,672‌

4,410‌

Affinivax

Next

Gen

Prod

Mileston

Event,

Acquisition

Date:

9/12/22,

Cost $3,454  (1)(2)(3)

7,349,672‌

1,617‌

Agios

Pharmaceuticals  (1)

398,930‌

11,202‌

Alector  (1)

344,770‌

3,182‌

Allakos 

966,912‌

8,141‌

Allogene

Therapeutics  (1)

1,862,898‌

11,718‌

Alnylam

Pharmaceuticals  (1)

1,534,426‌

364,656‌

Apellis

Pharmaceuticals  (1)

645,221‌

33,364‌

Arvinas  (1)

519,755‌

17,781‌

Ascendis

Pharma,

ADR  (1)

838,598‌

102,418‌

Avidity

Biosciences  (1)

1,761,822‌

39,095‌

BeiGene,

ADR  (1)

172,720‌

37,988‌

T.

ROWE

PRICE

Health

Sciences

Fund

17

Shares

$

Value

(Cost

and

value

in

$000s)

‡

Bicycle

Therapeutics,

ADR  (1)

254,670‌

7,538‌

Blueprint

Medicines  (1)

1,122,964‌

49,197‌

C4

Therapeutics  (1)

444,170‌

2,621‌

Centessa

Pharmaceuticals,

ADR  (1)

891,078‌

2,762‌

Cerevel

Therapeutics

Holdings  (1)

1,633,045‌

51,506‌

CRISPR

Therapeutics  (1)

260,117‌

10,574‌

Cytokinetics  (1)

427,378‌

19,583‌

Day

One

Biopharmaceuticals  (1)

474,062‌

10,202‌

Denali

Therapeutics  (1)

1,071,059‌

29,786‌

DICE

Therapeutics  (1)

678,522‌

21,170‌

Enanta

Pharmaceuticals  (1)

126,726‌

5,895‌

Entrada

Therapeutics  (1)

667,462‌

9,024‌

EQRx  (1)

896,285‌

2,205‌

EQRx,

Warrants,

12/20/26  (1)

227,520‌

61‌

Evotec

(EUR)  (1)

389,789‌

6,341‌

Exelixis  (1)

2,022,529‌

32,441‌

Exscientia,

ADR  (1)

192,196‌

1,024‌

Fate

Therapeutics  (1)

761,472‌

7,683‌

Flame

Biosciences,

Acquisition

Date:

9/28/20,

Cost $5,500  (1)(2)

(3)

839,721‌

3,854‌

F-star

Therapeutics  (1)

43,784‌

277‌

Generation

Bio  (1)

1,783,502‌

7,009‌

Genmab

(DKK)  (1)

313,129‌

132,389‌

Ginkgo

Bioworks,

Acquisition

Date:

9/17/21,

Cost $—  (1)(3)

212,706‌

112‌

Ginkgo

Bioworks,

Acquisition

Date:

9/17/21,

Cost $—  (1)(3)

212,706‌

102‌

Ginkgo

Bioworks,

Acquisition

Date:

9/17/21,

Cost $—  (1)(3)

212,706‌

93‌

Gyroscope

Therapeutics,

Milestone

Payment

1,

Acquisition

Date:

2/18/22,

Cost $5,684  (1)(2)(3)

5,683,928‌

2,785‌

Gyroscope

Therapeutics,

Milestone

Payment

2,

Acquisition

Date:

2/18/22,

Cost $3,788  (1)(2)(3)

3,788,007‌

1,023‌

Gyroscope

Therapeutics,

Milestone

Payment

3,

Acquisition

Date:

2/18/22,

Cost $3,788  (1)(2)(3)

3,788,007‌

985‌

IGM

Biosciences  (1)

304,853‌

5,186‌

Immuneering,

Class

A  (1)

1,582,394‌

7,675‌

Immunocore

Holdings,

ADR  (1)

1,055,554‌

60,241‌

Incyte  (1)

887,613‌

71,293‌

Insmed  (1)

2,406,290‌

48,078‌

Intellia

Therapeutics  (1)

382,509‌

13,346‌

Invivyd  (1)

288,950‌

433‌

Ionis

Pharmaceuticals  (1)

1,181,634‌

44,630‌

Iovance

Biotherapeutics  (1)

1,231,161‌

7,867‌

IVERIC

bio  (1)

1,835,482‌

39,298‌

Karuna

Therapeutics  (1)

601,875‌

118,269‌

Kodiak

Sciences  (1)

311,256‌

2,229‌

Kronos

Bio  (1)

111,866‌

181‌

Kymera

Therapeutics  (1)

775,316‌

19,352‌

T.

ROWE

PRICE

Health

Sciences

Fund

18

Shares

$

Value

(Cost

and

value

in

$000s)

‡

LianBio,

ADR  (1)

2,115,865‌

3,470‌

Longboard

Pharmaceuticals  (1)

502,243‌

1,587‌

Lyell

Immunopharma  (1)

1,295,155‌

4,494‌

MeiraGTx

Holdings  (1)

207,581‌

1,353‌

Mirati

Therapeutics  (1)

584,574‌

26,487‌

Moderna  (1)

1,045,625‌

187,815‌

Monte

Rosa

Therapeutics  (1)

1,153,343‌

8,777‌

MoonLake

Immunotherapeutics  (1)

678,545‌

7,125‌

Morphic

Holding  (1)

185,013‌

4,949‌

Novocure  (1)

1,176,250‌

86,278‌

Nurix

Therapeutics  (1)

274,027‌

3,009‌

Prelude

Therapeutics  (1)

181,040‌

1,094‌

Prime

Medicine,

Acquisition

Date:

4/19/21,

Cost $7,119  (1)(3)

522,748‌

9,227‌

Progenic

Pharmaceuticals,

CVR  (1)(2)

842,223‌

969‌

Prothena  (1)

649,910‌

39,157‌

PTC

Therapeutics  (1)

203,485‌

7,767‌

RAPT

Therapeutics  (1)

680,443‌

13,473‌

Regeneron

Pharmaceuticals  (1)

681,567‌

491,744‌

REGENXBIO  (1)

108,057‌

2,451‌

Relay

Therapeutics  (1)

1,045,229‌

15,616‌

Repligen  (1)

215,920‌

36,557‌

Replimune

Group  (1)

1,354,276‌

36,836‌

REVOLUTION

Medicines  (1)

1,007,238‌

23,992‌

Rocket

Pharmaceuticals  (1)

468,255‌

9,164‌

Sage

Therapeutics  (1)

550,322‌

20,989‌

Sana

Biotechnology  (1)

1,608,120‌

6,352‌

Sarepta

Therapeutics  (1)

456,820‌

59,195‌

Scholar

Rock,

Warrants,

12/31/25,

Acquisition

Date:

6/17/22,

Cost $—  (1)(3)

151,540‌

769‌

Scholar

Rock

Holding  (1)

1,843,863‌

16,687‌

SpringWorks

Therapeutics  (1)

159,530‌

4,149‌

Stoke

Therapeutics  (1)

255,805‌

2,361‌

Tenaya

Therapeutics  (1)

1,170,563‌

2,353‌

Theseus

Pharmaceuticals  (1)

1,009,115‌

5,025‌

Ultragenyx

Pharmaceutical  (1)

1,346,360‌

62,377‌

Vividion

Therapeutics,

Milestone

Payment,

Acquisition

Date:

8/25/21,

Cost $—  (1)(2)(3)

2,328,482‌

1,049‌

Vividion

Therapeutics,

Milestone

Payment,

Acquisition

Date:

8/25/21,

Cost $—  (1)(2)(3)

1,746,361‌

829‌

Vividion

Therapeutics,

Milestone

Payment

3,

Acquisition

Date:

8/25/21,

Cost $—  (1)(2)(3)

1,746,361‌

747‌

Xencor  (1)

762,860‌

19,865‌

Zai

Lab,

ADR  (1)

438,090‌

13,449‌

T.

ROWE

PRICE

Health

Sciences

Fund

19

Shares

$

Value

(Cost

and

value

in

$000s)

‡

Zentalis

Pharmaceuticals  (1)

582,982‌

11,741‌

2,788,043‌

Total

Biotechnology

3,580,774‌

CONSUMER

NONDURABLES

0.0%

Healthcare

Services

0.0%

Capsule,

Acquisition

Date:

4/7/21,

Cost $12,365  (1)(2)(3)

853,213‌

2,501‌

Total

Consumer

Nondurables

2,501‌

LIFE

SCIENCES

13.1%

Life

Sciences

13.1%

Agilent

Technologies 

2,165,312‌

324,039‌

Bio-Techne 

437,137‌

36,230‌

Bruker 

1,913,218‌

130,768‌

Danaher 

2,316,190‌

614,763‌

Dynamics

Special

Purpose,

Acquisition

Date:

12/20/21,

Cost $—  (1)(3)

115,996‌

155‌

Ginkgo

Bioworks

Holdings,

Class

A  (1)

2,329,124‌

3,936‌

Mettler-Toledo

International  (1)

50,097‌

72,413‌

Olink

Holding,

ADR  (1)

1,944,081‌

49,341‌

Pacific

Biosciences

of

California  (1)

2,592,999‌

21,211‌

Quanterix  (1)

114,664‌

1,588‌

Rapid

Micro

Biosystems,

Class

A  (1)

583,246‌

659‌

Seer  (1)

939,085‌

5,447‌

Senti

Biosciences  (1)

1,266,785‌

1,786‌

SomaLogic,

Warrants,

8/31/26  (1)

103,068‌

41‌

SomaLogic,

Earn

Out

Shares

$20,

Acquisition

Date:

9/2/21,

Cost $—  (1)(3)

3,873,442‌

14‌

Thermo

Fisher

Scientific 

1,503,088‌

827,736‌

Twist

Bioscience  (1)

298,281‌

7,102‌

Waters  (1)

64,820‌

22,206‌

Total

Life

Sciences

2,119,435‌

MISCELLANEOUS

0.0%

Miscellaneous

0.0%

Health

Sciences

Acquisitions

Corp

2  (1)

562,163‌

5,616‌

Total

Miscellaneous

5,616‌

PHARMACEUTICALS

16.9%

Major

Pharmaceuticals

16.9%

AbbVie 

1,721,272‌

278,175‌

AstraZeneca,

ADR 

7,999,227‌

542,348‌

Daiichi

Sankyo

(JPY) 

3,945,400‌

126,989‌

Eli

Lilly 

1,981,704‌

724,987‌

Merck 

5,109,928‌

566,946‌

Pfizer 

7,123,092‌

364,987‌

T.

ROWE

PRICE

Health

Sciences

Fund

20

Shares

$

Value

(Cost

and

value

in

$000s)

‡

Roche

Holding

(CHF) 

392,064‌

123,201‌

Total

Pharmaceuticals

2,727,633‌

PRODUCTS

&

DEVICES

16.1%

Capital

Equipment

0.5%

GE

HealthCare

Technologies  (1)

177,056‌

10,337‌

PROCEPT

BioRobotics  (1)

668,997‌

27,790‌

STERIS 

223,989‌

41,368‌

79,495‌

Implants

8.1%

Becton

Dickinson

&

Company 

1,138,233‌

289,453‌

Intuitive

Surgical  (1)

1,809,297‌

480,097‌

iRhythm

Technologies  (1)

180,858‌

16,941‌

Stryker 

1,500,949‌

366,967‌

Teleflex 

310,808‌

77,587‌

Verily

Life

Sciences,

Series

B,

Acquisition

Date:

1/23/19,

Cost $13,998  (1)(2)(3)

113,564‌

17,108‌

Zimmer

Biomet

Holdings 

447,573‌

57,066‌

1,305,219‌

Other

Products

&

Devices

7.5%

10X

Genomics,

Class

A  (1)

1,243,729‌

45,322‌

Argenx,

ADR  (1)

708,841‌

268,530‌

Avantor  (1)

4,213,720‌

88,867‌

Burning

Rock

Biotech,

ADR  (1)

187,049‌

421‌

Catalent  (1)

958,897‌

43,160‌

Cooper 

108,118‌

35,751‌

Dexcom  (1)

1,148,997‌

130,113‌

Hologic  (1)

1,954,618‌

146,225‌

Inari

Medical  (1)

382,006‌

24,280‌

Insulet  (1)

432,380‌

127,288‌

Lantheus

Holdings  (1)

126,300‌

6,436‌

Nevro  (1)

176,893‌

7,005‌

Pax

Labs,

Class

A,

Acquisition

Date:

4/18/19,

Cost $31,622  (1)(2)

(3)

8,397,988‌

5,543‌

Penumbra (1)

667,835‌

148,567‌

Saluda

Medical,

Warrants,

1/1/23,

Acquisition

Date:

1/20/22,

Cost $—  (1)(2)(3)

207,185‌

—‌

Shockwave

Medical  (1)

551,682‌

113,431‌

Warby

Parker,

Class

A  (1)

1,562,906‌

21,084‌

1,212,023‌

Total

Products

&

Devices

2,596,737‌

T.

ROWE

PRICE

Health

Sciences

Fund

21

Shares

$

Value

(Cost

and

value

in

$000s)

‡

SERVICES

21.8%

Distribution

0.1%

Option

Care

Health  (1)

622,214‌

18,722‌

18,722‌

Information

0.9%

Doximity,

Class

A  (1)

1,255,648‌

42,140‌

Sema4

Holdings  (1)

1,150,482‌

303‌

Sema4

Holdings,

Warrants,

7/22/26  (1)

236,011‌

4‌

Sophia

Genetics  (1)

635,323‌

1,309‌

Veeva

Systems,

Class

A  (1)

579,779‌

93,565‌

137,321‌

Other

Services

0.9%

Certara (1)

461,617‌

7,418‌

Elanco

Animal

Health  (1)

625,900‌

7,648‌

Guardant

Health  (1)

1,092,484‌

29,716‌

West

Pharmaceutical

Services 

348,364‌

81,987‌

Wuxi

Biologics

Cayman

(HKD)  (1)

3,159,500‌

23,930‌

150,699‌

Payors

18.8%

Alignment

Healthcare  (1)

1,216,902‌

14,311‌

Centene  (1)

3,321,294‌

272,379‌

Cigna 

711,926‌

235,890‌

Elevance

Health 

995,033‌

510,422‌

Humana 

701,570‌

359,337‌

Molina

Healthcare  (1)

759,446‌

250,784‌

UnitedHealth

Group 

2,644,430‌

1,402,024‌

3,045,147‌

Providers

1.1%

agilon

health  (1)

462,354‌

7,462‌

HCA

Healthcare 

608,498‌

146,015‌

Oak

Street

Health  (1)

512,163‌

11,017‌

Surgery

Partners  (1)

322,715‌

8,991‌

173,485‌

Total

Services

3,525,374‌

Total

Miscellaneous

Common

Stocks

 4.2%  (4)

672,525‌

Total

Common

Stocks

(Cost

$7,580,839)

15,230,595‌

T.

ROWE

PRICE

Health

Sciences

Fund

22

Shares

$

Value

(Cost

and

value

in

$000s)

‡

CONVERTIBLE

PREFERRED

STOCKS

4.4%

BIOTECHNOLOGY

1.4%

Other

Biotechnology

1.4%

Arbor

Bio,

Series

B,

Acquisition

Date:

10/29/21,

Cost $8,828  (1)

(2)(3)

532,759‌

8,828‌

Chroma

Medicine,

Series

A,

Acquisition

Date:

10/12/21,

Cost $11,040  (1)(2)(3)(5)

5,207,526‌

11,040‌

Delfi

Diagnostics,

Series

A,

Acquisition

Date:

1/12/21-4/7/22,

Cost $7,107  (1)(2)(3)

3,426,868‌

16,605‌

Delfi

Diagnostics,

Series

B,

Acquisition

Date:

6/10/22,

Cost $8,980  (1)(2)(3)

1,853,138‌

8,980‌

Eikon

Therapeutics,

Series

B,

Acquisition

Date:

12/3/21,

Cost $18,021  (1)(2)(3)

1,018,820‌

18,022‌

EndeavorBio,

Series

B,

Acquisition

Date:

1/21/22,

Cost $8,808  (1)

(2)(3)

1,867,734‌

8,808‌

FOG

Pharma,

Acquisition

Date:

11/17/22,

Cost $6,621  (1)(2)(3)

615,203‌

6,621‌

FOG

Pharma,

Series

C,

Acquisition

Date:

1/11/21-8/2/21,

Cost $6,251  (1)(2)(3)

431,391‌

4,643‌

Generate

Bio,

Series

B,

Acquisition

Date:

9/2/21,

Cost $22,096  (1)

(2)(3)

1,864,632‌

22,096‌

Genesis

Therapeutics,

Series

A,

Acquisition

Date:

11/24/20,

Cost $4,236  (1)(2)(3)

829,412‌

4,236‌

Insitro,

Series

B,

Acquisition

Date:

5/21/20,

Cost $5,505  (1)(2)(3)

883,580‌

16,162‌

Insitro,

Series

C,

Acquisition

Date:

4/7/21,

Cost $10,762  (1)(2)(3)

588,382‌

10,762‌

Laronde,

Series

B,

Acquisition

Date:

7/28/21,

Cost $32,757  (1)(2)

(3)

1,169,887‌

6,551‌

Nutcracker

Therapeutics,

Series

C,

Acquisition

Date:

8/27/21,

Cost $11,050  (1)(2)(3)

1,027,785‌

11,050‌

Odyssey

Therapeutics,

Series

B,

Acquisition

Date:

5/13/22,

Cost $7,048  (1)(2)(3)

1,115,915‌

7,048‌

Ring

Therapeutics,

Acquisition

Date:

10/7/22,

Cost $4,414  (1)(2)

(3)

479,818‌

4,414‌

Ring

Therapeutics,

Series

B,

Acquisition

Date:

4/12/21,

Cost $9,004  (1)(2)(3)

978,705‌

9,004‌

SalioGen

Therapeutics,

Series

B,

Acquisition

Date:

12/10/21,

Cost $11,024  (1)(2)(3)

104,129‌

11,024‌

Scribe

Therapeutics,

Series

B,

Acquisition

Date:

3/17/21,

Cost $6,219  (1)(2)(3)

1,027,755‌

6,219‌

Sionna

Therapeutics,

Series

B,

Acquisition

Date:

2/2/22,

Cost $5,284  (1)(2)(3)

541,277‌

5,284‌

Tessera

Therapeutics,

Series

C,

Acquisition

Date:

2/25/22,

Cost $7,915  (1)(2)(3)

387,032‌

7,915‌

Treeline

Bioscience,

Series

A,

Acquisition

Date:

4/9/21-9/26/22,

Cost $18,552  (1)(2)(3)

2,370,150‌

18,552‌

Total

Biotechnology

223,864‌

T.

ROWE

PRICE

Health

Sciences

Fund

23

Shares

$

Value

(Cost

and

value

in

$000s)

‡

CONSUMER

NONDURABLES

0.2%

Healthcare

Services

0.2%

Color

Health,

Series

D,

Acquisition

Date:

12/17/20,

Cost $11,180  (1)(2)(3)

296,922‌

12,144‌

Color

Health,

Series

D-1,

Acquisition

Date:

1/13/20,

Cost $9,358  (1)(2)(3)

438,696‌

17,942‌

Color

Health,

Series

E,

Acquisition

Date:

10/26/21,

Cost $4,414  (1)

(2)(3)

44,149‌

1,806‌

Total

Consumer

Nondurables

31,892‌

LIFE

SCIENCES

1.1%

Life

Sciences

1.1%

Cellanome,

Series

A,

Acquisition

Date:

12/30/21,

Cost $11,023  (1)

(2)(3)(5)

1,993,387‌

13,874‌

Chromacode,

Series

D-1,

Acquisition

Date:

2/28/22,

Cost $2,202  (1)(2)(3)

3,137,582‌

2,040‌

Chromacode,

Series

D-2,

Acquisition

Date:

2/28/22,

Cost $2,202  (1)(2)(3)

2,605,184‌

1,693‌

Clear

Labs,

Series

C,

Acquisition

Date:

5/13/21,

Cost $13,294  (1)

(2)(3)

3,830,773‌

13,294‌

DNA

Script,

Series

C,

Acquisition

Date:

12/16/21,

Cost $21,371

(EUR)  (1)(2)(3)

25,201‌

20,232‌

Element

Biosciences,

Series

C,

Acquisition

Date:

6/21/21,

Cost $17,704  (1)(2)(3)

861,217‌

17,704‌

Inscripta,

Series

E,

Acquisition

Date:

3/30/21,

Cost $12,829  (1)(2)

(3)

1,452,941‌

8,107‌

Lumicks

Tech,

Series

D,

Acquisition

Date:

4/14/21,

Cost $8,875  (1)(2)(3)

4,954‌

9,585‌

National

Resilience,

Series

B,

Acquisition

Date:

10/23/20,

Cost $16,458  (1)(2)(3)

1,204,832‌

73,170‌

National

Resilience,

Series

C,

Acquisition

Date:

6/9/21,

Cost $18,957  (1)(2)(3)

426,855‌

25,923‌

Total

Life

Sciences

185,622‌

PRODUCTS

&

DEVICES

0.3%

Capital

Equipment

0.1%

Reflexion

Medical,

Series

C,

Acquisition

Date:

4/3/18,

Cost $4,243  (1)(2)(3)

2,507,885‌

5,945‌

Reflexion

Medical,

Series

D,

Acquisition

Date:

4/3/20,

Cost $2,142  (1)(2)(3)

1,123,437‌

2,663‌

Reflexion

Medical,

Series

E,

Acquisition

Date:

3/1/22,

Cost $4,403  (1)(2)(3)

1,857,286‌

4,403‌

13,011‌

Implants

0.1%

Kardium,

Series

D-5,

Acquisition

Date:

11/29/18,

Cost $8,574  (1)

(2)(3)(5)

8,849,057‌

8,989‌

T.

ROWE

PRICE

Health

Sciences

Fund

24

Shares

$

Value

(Cost

and

value

in

$000s)

‡

Kardium,

Series

D-6,

Acquisition

Date:

1/8/21,

Cost $12,516  (1)

(2)(3)(5)

12,320,393‌

12,516‌

21,505‌

Other

Products

&

Devices

0.1%

Saluda

Medical,

Series

D,

Acquisition

Date:

1/20/22,

Cost $8,809  (1)(2)(3)

690,617‌

8,809‌

8,809‌

Total

Products

&

Devices

43,325‌

SERVICES

1.4%

Information

0.0%

Cleerly,

Series

C,

Acquisition

Date:

7/8/22,

Cost $6,904  (1)(2)(3)

586,029‌

6,904‌

6,904‌

Other

Services

1.3%

Caris

Life

Sciences,

Series

C,

Acquisition

Date:

8/14/20,

Cost $10,374  (1)(2)(3)

3,758,668‌

24,732‌

Caris

Life

Sciences,

Series

D,

Acquisition

Date:

5/11/21,

Cost $18,471  (1)(2)(3)

2,280,334‌

15,005‌

Freenome

Holdings,

Series

B,

Acquisition

Date:

6/24/19,

Cost $7,103  (1)(2)(3)

1,558,570‌

18,189‌

Freenome

Holdings,

Series

C,

Acquisition

Date:

8/14/20,

Cost $6,139  (1)(2)(3)

928,231‌

10,832‌

Freenome

Holdings,

Series

D,

Acquisition

Date:

11/22/21,

Cost $3,971  (1)(2)(3)

526,504‌

6,144‌

PrognomIQ,

Series

A-4,

Acquisition

Date:

11/15/19,

Cost $1,356  (1)(2)(3)(5)

593,540‌

1,816‌

PrognomIQ,

Series

A-5,

Acquisition

Date:

5/12/20,

Cost $1,174  (1)

(2)(3)(5)

513,797‌

1,572‌

PrognomIQ,

Series

B,

Acquisition

Date:

9/11/20,

Cost $8,533  (1)

(2)(3)(5)

3,734,140‌

11,427‌

PrognomIQ,

Series

C,

Acquisition

Date:

2/16/22,

Cost $3,498  (1)

(2)(3)(5)

1,143,244‌

3,498‌

Tempus

Labs,

Series

D,

Acquisition

Date:

3/16/18,

Cost $8,876  (1)

(2)(3)

946,886‌

55,753‌

Tempus

Labs,

Series

E,

Acquisition

Date:

8/23/18,

Cost $10,607  (1)(2)(3)

633,505‌

38,289‌

Tempus

Labs,

Series

F,

Acquisition

Date:

4/30/19,

Cost $4,279  (1)

(2)(3)

172,826‌

10,584‌

Tempus

Labs,

Series

G,

Acquisition

Date:

2/6/20,

Cost $4,285  (1)

(2)(3)

111,715‌

6,924‌

Tempus

Labs,

Series

G-2,

Acquisition

Date:

11/19/20,

Cost $6,720  (1)(2)(3)

117,271‌

6,592‌

211,357‌

T.

ROWE

PRICE

Health

Sciences

Fund

25

Shares

$

Value

(Cost

and

value

in

$000s)

‡

Providers

0.1%

Honor

Technology,

Series

D,

Acquisition

Date:

10/16/20,

Cost $7,540  (1)(2)(3)

3,130,941‌

7,201‌

Honor

Technology,

Series

E,

Acquisition

Date:

9/29/21,

Cost $6,626  (1)(2)(3)

2,095,807‌

4,821‌

12,022‌

Total

Services

230,283‌

Total

Convertible

Preferred

Stocks

(Cost

$538,531)

714,986‌

PREFERRED

STOCKS

0.6%

LIFE

SCIENCES

0.6%

Life

Sciences

0.6%

Sartorius

(EUR) 

240,070‌

94,798‌

Total

Life

Sciences

94,798‌

Total

Preferred

Stocks

(Cost

$46,391)

94,798‌

SHORT-TERM

INVESTMENTS

1.0%

Money

Market

Funds

1.0%

T.

Rowe

Price

Government

Reserve

Fund,

4.30%  (5)(6)

158,975,596‌

158,976‌

Total

Short-Term

Investments

(Cost

$158,976)

158,976‌

Total

Investments

in

Securities

100.2%

of

Net

Assets

(Cost

$8,324,737)

$

16,199,355‌

‡

Shares

are

denominated

in

U.S.

dollars

unless

otherwise

noted.

(1)

Non-income

producing

(2)

See

Note

2.

Level

3

in

fair

value

hierarchy.

(3)

Security

cannot

be

offered

for

public

resale

without

first

being

registered

under

the

Securities

Act

of

1933

and

related

rules

("restricted

security").

Acquisition

date

represents

the

day

on

which

an

enforceable

right

to

acquire

such

security

is

obtained

and

is

presented

along

with

related

cost

in

the

security

description.

The

fund

may

have

registration

rights

for

certain

restricted

securities.

Any

costs

related

to

such

registration

are

generally

borne

by

the

issuer.

The

aggregate

value

of

restricted

securities

(excluding

144A

holdings)

at

period

end

amounts

to

$785,328

and

represents

4.9%

of

net

assets.

(4)

The

identity

of

certain

securities

has

been

concealed

to

protect

the

fund

while

it

completes

a

purchase

or

selling

program

for

the

securities.

(5)

Affiliated

Companies

(6)

Seven-day

yield

T.

ROWE

PRICE

Health

Sciences

Fund

26

ADR

American

Depositary

Receipts

CHF

Swiss

Franc

CVR

Contingent

Value

Rights

DKK

Danish

Krone

EC

Escrow

CUSIP;

represents

a

beneficial

interest

in

a

residual

pool

of

assets;

the

amount

and

timing

of

future

distributions,

if

any,

is

uncertain;

when

presented,

interest

rate

and

maturity

date

are

those

of

the

original

security.

EUR

Euro

HKD

Hong

Kong

Dollar

JPY

Japanese

Yen

T.

ROWE

PRICE

Health

Sciences

Fund

27

AFFILIATED

COMPANIES

($000s)

The

fund

may

invest

in

certain

securities

that

are

considered

affiliated

companies.

As

defined

by

the

1940

Act,

an

affiliated

company

is

one

in

which

the

fund

owns

5%

or

more

of

the

outstanding

voting

securities,

or

a

company

that

is

under

common

ownership

or

control.

The

following

securities

were

considered

affiliated

companies

for

all

or

some

portion

of

the

year

ended

December

31,

2022.

Net

realized

gain

(loss),

investment

income,

change

in

net

unrealized

gain/loss,

and

purchase

and

sales

cost

reflect

all

activity

for

the

period

then

ended.

Affiliate

Net

Realized

Gain

(Loss)

Change

in

Net

Unrealized

Gain/Loss

Investment

Income

Cellanome,

Series

A 

$

—‌

$

2,851‌

$

—‌

Chroma

Medicine,

Series

A 

—‌

—‌

—‌

Immuneering,

Class

A 

(1,127‌)

(6,145‌)

—‌

Kardium,

Series

D-5 

—‌

—‌

—‌

Kardium,

Series

D-6 

—‌

—‌

—‌

PrognomIQ,

Series

A-4 

—‌

459‌

—‌

PrognomIQ,

Series

A-5 

—‌

398‌

—‌

PrognomIQ,

Series

B 

—‌

2,894‌

—‌

PrognomIQ,

Series

C 

—‌

—‌

—‌

SomaLogic,

Warrants,

8/31/26 

(22‌)

(305‌)

—‌

SomaLogic,

Earn

Out

Shares

$20 

—‌

(368‌)

—‌

Treeline

Bioscience,

Series

A 

—‌

—‌

—‌

T.

Rowe

Price

Government

Reserve

Fund,

4.30%

—‌

—‌

385‌

Affiliates

not

held

at

period

end

(4,554‌)

(29,640‌)

—‌

Totals

$

(5,703‌)#

$

(29,856‌)

$

385‌+

T.

ROWE

PRICE

Health

Sciences

Fund

28

The

accompanying

notes

are

an

integral

part

of

these

financial

statements.

AFFILIATED

COMPANIES

(CONTINUED)

($000s)

Supplementary

Investment

Schedule

Affiliate

Value

12/31/21

Purchase

Cost

Sales

Cost

Value

12/31/22

Cellanome,

Series

A 

$

11,023‌

$

—‌

$

—‌

$

13,874‌

Chroma

Medicine,

Series

A 

11,040‌

—‌

—‌

11,040‌

Immuneering,

Class

A 

*

9,467‌

2,140‌

*

Kardium,

Series

D-5 

8,989‌

—‌

—‌

8,989‌

Kardium,

Series

D-6 

12,516‌

—‌

—‌

12,516‌

PrognomIQ,

Series

A-4 

1,357‌

—‌

—‌

1,816‌

PrognomIQ,

Series

A-5 

1,174‌

—‌

—‌

1,572‌

PrognomIQ,

Series

B 

8,533‌

—‌

—‌

11,427‌

PrognomIQ,

Series

C 

—‌

3,498‌

—‌

3,498‌

SomaLogic 

14,966‌

15,668‌

28,159‌

—‌

SomaLogic,

Warrants,

8/31/26 

372‌

—‌

26‌

*

SomaLogic,

Class

B 

42,833‌

—‌

15,668‌

—‌

SomaLogic,

Earn

Out

Shares

$20 

382‌

—‌

—‌

*

Treeline

Bioscience,

Series

A 

*

11,332‌

—‌

*

T.

Rowe

Price

Government

Reserve

Fund,

4.30%

12,084‌

  ¤

  ¤

158,976‌

Total

$

223,708‌^

#

Capital

gain

distributions

from

underlying

Price

funds

represented

$0

of

the

net

realized

gain

(loss).

+

Investment

income

comprised

$385

of

dividend

income

and

$0

of

interest

income.

¤

Purchase

and

sale

information

not

shown

for

cash

management

funds.

^

The

cost

basis

of

investments

in

affiliated

companies

was

$216,690.

*

On

the

date

indicated,

issuer

was

held

but

not

considered

an

affiliated

company.

T.

ROWE

PRICE

Health

Sciences

Fund

December

31,

2022

Statement

of

Assets

and

Liabilities

29

($000s,

except

shares

and

per

share

amounts)

The

accompanying

notes

are

an

integral

part

of

these

financial

statements.

Assets

Investments

in

securities,

at

value

(cost

$8,324,737)

$

16,199,355‌

Receivable

for

investment

securities

sold

19,602‌

Receivable

for

shares

sold

9,592‌

Dividends

receivable

6,753‌

Foreign

currency

(cost

$590)

599‌

Other

assets

5,302‌

Total

assets

16,241,203‌

Liabilities

Payable

for

shares

redeemed

39,430‌

Payable

for

investment

securities

purchased

17,387‌

Investment

management

fees

payable

8,914‌

Due

to

affiliates

796‌

Payable

to

directors

10‌

Other

liabilities

1,675‌

Total

liabilities

68,212‌

NET

ASSETS

$

16,172,991‌

Net

Assets

Consist

of:

Total

distributable

earnings

(loss)

$

7,680,227‌

Paid-in

capital

applicable

to

179,996,928

shares

of

$0.0001

par

value

capital

stock

outstanding;

1,000,000,000

shares

authorized

8,492,764‌

NET

ASSETS

$

16,172,991‌

NET

ASSET

VALUE

PER

SHARE

Investor

Class

($10,235,148,927

/

113,952,879

shares

outstanding)

$

89.82‌

I

Class

($5,937,842,426

/

66,044,049

shares

outstanding)

$

89.91‌

T.

ROWE

PRICE

Health

Sciences

Fund

Statement

of

Operations

30

($000s)

The

accompanying

notes

are

an

integral

part

of

these

financial

statements.

Year

Ended

12/31/22

Investment

Income

(Loss)

Income

Dividend

(net

of

foreign

taxes

of

$1,385)

$

115,915‌

Other

9‌

Total

income

115,924‌

Expenses

Investment

management

103,891‌

Shareholder

servicing

Investor

Class

$

17,099‌

I

Class

1,254‌

18,353‌

Prospectus

and

shareholder

reports

Investor

Class

341‌

I

Class

46‌

387‌

Custody

and

accounting

586‌

Legal

and

audit

292‌

Registration

216‌

Directors

43‌

Miscellaneous

438‌

Total

expenses

124,206‌

Net

investment

loss

(8,282‌)

T.

ROWE

PRICE

Health

Sciences

Fund

Statement

of

Operations

31

($000s)

The

accompanying

notes

are

an

integral

part

of

these

financial

statements.

Year

Ended

12/31/22

Realized

and

Unrealized

Gain

/

Loss

–

Net

realized

gain

(loss)

Securities

(13,937‌)

Foreign

currency

transactions

(660‌)

Net

realized

loss

(14,597‌)

Change

in

net

unrealized

gain

/

loss

Securities

(2,384,200‌)

Other

assets

and

liabilities

denominated

in

foreign

currencies

(61‌)

Change

in

net

unrealized

gain

/

loss

(2,384,261‌)

Net

realized

and

unrealized

gain

/

loss

(2,398,858‌)

DECREASE

IN

NET

ASSETS

FROM

OPERATIONS

$

(2,407,140‌)

T.

ROWE

PRICE

Health

Sciences

Fund

Statement

of

Changes

in

Net

Assets

32

($000s)

Year

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Ended

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

12/31/22

12/31/21

Increase

(Decrease)

in

Net

Assets

Operations

Net

investment

loss

$

(8,282‌)

$

(37,152‌)

Net

realized

gain

(loss)

(14,597‌)

1,251,022‌

Change

in

net

unrealized

gain

/

loss

(2,384,261‌)

1,085,757‌

Increase

(decrease)

in

net

assets

from

operations

(2,407,140‌)

2,299,627‌

Distributions

to

shareholders

Net

earnings

Investor

Class

(179,171‌)

(1,202,597‌)

I

Class

(103,404‌)

(161,546‌)

Decrease

in

net

assets

from

distributions

(282,575‌)

(1,364,143‌)

Capital

share

transactions

*

Shares

sold

Investor

Class

1,236,166‌

1,935,820‌

I

Class

4,332,246‌

667,635‌

Distributions

reinvested

Investor

Class

172,182‌

1,144,471‌

I

Class

97,063‌

155,182‌

Shares

redeemed

Investor

Class

(5,916,581‌)

(2,473,973‌)

I

Class

(567,212‌)

(287,745‌)

Increase

(decrease)

in

net

assets

from

capital

share

transactions

(646,136‌)

1,141,390‌

T.

ROWE

PRICE

Health

Sciences

Fund

Statement

of

Changes

in

Net

Assets

33

($000s)

The

accompanying

notes

are

an

integral

part

of

these

financial

statements.

Year

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Ended

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

12/31/22

12/31/21

Net

Assets

Increase

(decrease)

during

period

(3,335,851‌)

2,076,874‌

Beginning

of

period

19,508,842‌

17,431,968‌

End

of

period

$

16,172,991‌

$

19,508,842‌

*Share

information

(000s)

Shares

sold

Investor

Class

13,681‌

18,329‌

I

Class

49,285‌

6,269‌

Distributions

reinvested

Investor

Class

1,895‌

11,183‌

I

Class

1,067‌

1,517‌

Shares

redeemed

Investor

Class

(67,007‌)

(23,488‌)

I

Class

(6,369‌)

(2,712‌)

Increase

(decrease)

in

shares

outstanding

(7,448‌)

11,098‌

T.

ROWE

PRICE

Health

Sciences

Fund

NOTES

TO

FINANCIAL

STATEMENTS

34

T.

Rowe

Price

Health

Sciences

Fund,

Inc.

(the

fund) is

registered

under

the

Investment

Company

Act

of

1940

(the

1940

Act)

as a

diversified,

open-end

management

investment

company. The

fund

seeks

long-term

capital

appreciation.

The

fund

has

two classes

of

shares:

the

Health

Sciences

Fund

(Investor

Class)

and

the

Health

Sciences

Fund–I

Class

(I

Class).

I

Class

shares

require

a

$500,000

initial

investment

minimum,

although

the

minimum

generally

is

waived

or

reduced

for

financial

intermediaries,

eligible

retirement

plans,

and

certain

other

accounts.

Prior

to

November

15,

2021,

the

initial

investment

minimum

was

$1

million

and

was

generally

waived

for

financial

intermediaries,

eligible

retirement

plans,

and

other

certain

accounts.

As

a

result

of

the

reduction

in

the

I

Class

minimum,

certain

assets

transferred

from

the

Investor

Class

to

the

I

Class.

This

transfer

of

shares

from

Investor

Class

to

I

Class

is

reflected

in

the

Statement

of

Changes

in

Net

Assets

within

the

Capital

shares

transactions

as

Shares

redeemed

and

Shares

sold,

respectively. Each

class

has

exclusive

voting

rights

on

matters

related

solely

to

that

class;

separate

voting

rights

on

matters

that

relate

to

both

classes;

and,

in

all

other

respects,

the

same

rights

and

obligations

as

the

other

class.

NOTE

1

-

SIGNIFICANT

ACCOUNTING

POLICIES 

Basis

of

Preparation

 The fund

is

an

investment

company

and

follows

accounting

and

reporting

guidance

in

the

Financial

Accounting

Standards

Board

(FASB)

Accounting

Standards

Codification

Topic

946

(ASC

946).

The

accompanying

financial

statements

were

prepared

in

accordance

with

accounting

principles

generally

accepted

in

the

United

States

of

America

(GAAP),

including,

but

not

limited

to,

ASC

946.

GAAP

requires

the

use

of

estimates

made

by

management.

Management

believes

that

estimates

and

valuations

are

appropriate;

however,

actual

results

may

differ

from

those

estimates,

and

the

valuations

reflected

in

the

accompanying

financial

statements

may

differ

from

the

value

ultimately

realized

upon

sale

or

maturity.

Investment

Transactions,

Investment

Income,

and

Distributions

Investment

transactions

are

accounted

for

on

the

trade

date

basis.

Income

and

expenses

are

recorded

on

the

accrual

basis.

Realized

gains

and

losses

are

reported

on

the

identified

cost

basis.

Income

tax-related

interest

and

penalties,

if

incurred,

are

recorded

as

income

tax

expense.

Dividends

received

from

mutual

fund

investments

are

reflected

as

dividend

income;

capital

gain

distributions

are

reflected

as

realized

gain/loss.

Dividend

income

and

capital

gain

distributions

are

recorded

on

the

ex-dividend

date.

Non-cash

dividends,

if

any,

are

recorded

at

the

fair

market

value

of

the

asset

received.

Proceeds

from

litigation

payments,

if

any,

are

included

in

either

net

realized

gain

(loss)

or

change

T.

ROWE

PRICE

Health

Sciences

Fund

35

in

net

unrealized

gain/loss

from

securities.

Distributions

to

shareholders

are

recorded

on

the

ex-dividend

date.

Income

distributions,

if

any,

are

declared

and

paid

by

each

class annually.

A

capital

gain

distribution,

if

any, may

also

be

declared

and

paid

by

the

fund

annually.

Currency

Translation

 Assets,

including

investments,

and

liabilities

denominated

in

foreign

currencies

are

translated

into

U.S.

dollar

values

each

day

at

the

prevailing

exchange

rate,

using

the

mean

of

the

bid

and

asked

prices

of

such

currencies

against

U.S.

dollars

as

provided

by

an

outside

pricing

service.

Purchases

and

sales

of

securities,

income,

and

expenses

are

translated

into

U.S.

dollars

at

the

prevailing

exchange

rate

on

the

respective

date

of

such

transaction.

The

effect

of

changes

in

foreign

currency

exchange

rates

on

realized

and

unrealized

security

gains

and

losses

is

not

bifurcated

from

the

portion

attributable

to

changes

in

market

prices.

Class

Accounting

 Shareholder

servicing,

prospectus,

and

shareholder

report

expenses

incurred

by

each

class

are

charged

directly

to

the

class

to

which

they

relate.

Expenses

common

to all classes,

investment

income,

and

realized

and

unrealized

gains

and

losses

are

allocated

to

the

classes

based

upon

the

relative

daily

net

assets

of

each

class.

Capital

Transactions

 Each

investor’s

interest

in

the

net

assets

of the

fund

is

represented

by

fund

shares. The

fund’s

net

asset

value

(NAV)

per

share

is

computed

at

the

close

of

the

New

York

Stock

Exchange

(NYSE),

normally

4

p.m.

ET,

each

day

the

NYSE

is

open

for

business.

However,

the

NAV

per

share

may

be

calculated

at

a

time

other

than

the

normal

close

of

the

NYSE

if

trading

on

the

NYSE

is

restricted,

if

the

NYSE

closes

earlier,

or

as

may

be

permitted

by

the

SEC.

Purchases

and

redemptions

of

fund

shares

are

transacted

at

the

next-computed

NAV

per

share,

after

receipt

of

the

transaction

order

by

T.

Rowe

Price

Associates,

Inc.,

or

its

agents.

New

Accounting

Guidance

 In

June

2022,

the

FASB

issued

Accounting

Standards

Update

(ASU),

ASU

2022-03,

Fair

Value

Measurement

(Topic

820)

–

Fair

Value

Measurement

of

Equity

Securities

Subject

to

Contractual

Sale

Restrictions,

which

clarifies

that

a

contractual

restriction

on

the

sale

of

an

equity

security

is

not

considered

part

of

the

unit

of

account

of

the

equity

security

and,

therefore,

is

not

considered

in

measuring

fair

value.

The

amendments

under

this

ASU

are

effective

for

fiscal

years

beginning

after

December

15,

2023;

however,

the

fund

opted

to

early

adopt,

as

permitted,

effective

December

1,

2022. Adoption

of

the

guidance

did not

have

a

material

impact

on

the fund's

financial  statements.

Indemnification

 In

the

normal

course

of

business, the

fund

may

provide

indemnification

in

connection

with

its

officers

and

directors,

service

providers,

and/or

private

company

investments. The

fund’s

maximum

exposure

under

these

arrangements

is

unknown;

however,

the

risk

of

material

loss

is

currently

considered

to

be

remote.

T.

ROWE

PRICE

Health

Sciences

Fund

36

NOTE

2

-

VALUATION 

Fair

Value

  The

fund’s

financial

instruments

are

valued

at

the

close

of

the

NYSE

and

are

reported

at

fair

value,

which

GAAP

defines

as

the

price

that

would

be

received

to

sell

an

asset

or

paid

to

transfer

a

liability

in

an

orderly

transaction

between

market

participants

at

the

measurement

date. The fund’s

Board

of

Directors

(the

Board)

has

designated

T.

Rowe

Price

Associates,

Inc.

as

the

fund’s

valuation

designee

(Valuation

Designee).

Subject

to

oversight

by

the

Board,

the

Valuation

Designee

performs

the

following

functions

in

performing

fair

value

determinations:

assesses

and

manages

valuation

risks;

establishes

and

applies

fair

value

methodologies;

tests

fair

value

methodologies;

and

evaluates

pricing

vendors

and

pricing

agents.

The

duties

and

responsibilities

of

the

Valuation

Designee

are

performed

by

its

Valuation

Committee. The

Valuation

Designee provides

periodic

reporting

to

the

Board

on

valuation

matters.

Various

valuation

techniques

and

inputs

are

used

to

determine

the

fair

value

of

financial

instruments.

GAAP

establishes

the

following

fair

value

hierarchy

that

categorizes

the

inputs

used

to

measure

fair

value:

Level

1

–

quoted

prices

(unadjusted)

in

active

markets

for

identical

financial

instruments

that

the

fund

can

access

at

the

reporting

date

Level

2

–

inputs

other

than

Level

1

quoted

prices

that

are

observable,

either

directly

or

indirectly

(including,

but

not

limited

to,

quoted

prices

for

similar

financial

instruments

in

active

markets,

quoted

prices

for

identical

or

similar

financial

instruments

in

inactive

markets,

interest

rates

and

yield

curves,

implied

volatilities,

and

credit

spreads)

Level

3

–

unobservable

inputs

(including

the Valuation

Designee’s assumptions

in

determining

fair

value)

Observable

inputs

are

developed

using

market

data,

such

as

publicly

available

information

about

actual

events

or

transactions,

and

reflect

the

assumptions

that

market

participants

would

use

to

price

the

financial

instrument.

Unobservable

inputs

are

those

for

which

market

data

are

not

available

and

are

developed

using

the

best

information

available

about

the

assumptions

that

market

participants

would

use

to

price

the

financial

instrument.

GAAP

requires

valuation

techniques

to

maximize

the

use

of

relevant

observable

inputs

and

minimize

the

use

of

unobservable

inputs.

When

multiple

inputs

are

used

to

derive

fair

value,

the

financial

instrument

is

assigned

to

the

level

within

the

fair

value

hierarchy

based

on

the

lowest-level

input

that

is

significant

to

the

fair

value

of

the

financial

instrument.

Input

levels

are

not

necessarily

an

indication

of

the

risk

or

liquidity

associated

with

financial

instruments

at

that

level

but

rather

the

degree

of

judgment

used

in

determining

those

values.

T.

ROWE

PRICE

Health

Sciences

Fund

37

Valuation

Techniques 

Equity

securities,

including

exchange-traded

funds, listed

or

regularly

traded

on

a

securities

exchange

or

in

the

over-the-counter

(OTC)

market

are

valued

at

the

last

quoted

sale

price

or,

for

certain

markets,

the

official

closing

price

at

the

time

the

valuations

are

made.

OTC

Bulletin

Board

securities

are

valued

at

the

mean

of

the

closing

bid

and

asked

prices.

A

security

that

is

listed

or

traded

on

more

than

one

exchange

is

valued

at

the

quotation

on

the

exchange

determined

to

be

the

primary

market

for

such

security.

Listed

securities

not

traded

on

a

particular

day

are

valued

at

the

mean

of

the

closing

bid

and

asked

prices

for

domestic

securities

and

the

last

quoted

sale

or

closing

price

for

international

securities.

The

last

quoted

prices

of

non-U.S.

equity

securities

may

be

adjusted

to

reflect

the

fair

value

of

such

securities

at

the

close

of

the

NYSE,

if

the Valuation

Designee

determines

that

developments

between

the

close

of

a

foreign

market

and

the

close

of

the

NYSE

will

affect

the

value

of

some

or

all

of the

fund’s

portfolio

securities.

Each

business

day,

the

Valuation

Designee uses

information

from

outside

pricing

services

to

evaluate

the

quoted

prices

of

portfolio

securities

and,

if

appropriate,

decide whether

it

is

necessary

to

adjust

quoted

prices

to

reflect

fair

value

by

reviewing

a

variety

of

factors,

including

developments

in

foreign

markets,

the

performance

of

U.S.

securities

markets,

and

the

performance

of

instruments

trading

in

U.S.

markets

that

represent

foreign

securities

and

baskets

of

foreign

securities. The Valuation

Designee

uses

outside

pricing

services

to

provide

it

with

quoted

prices

and

information

to

evaluate

or

adjust

those

prices.

The Valuation

Designee

cannot

predict

how

often

it

will

use

quoted

prices

and

how

often

it

will

determine

it

necessary

to

adjust

those

prices

to

reflect

fair

value.

Investments

in

mutual

funds

are

valued

at

the

mutual

fund’s

closing

NAV

per

share

on

the

day

of

valuation.

Assets

and

liabilities

other

than

financial

instruments,

including

short-term

receivables

and

payables,

are

carried

at

cost,

or

estimated

realizable

value,

if

less,

which

approximates

fair

value. 

Investments

for

which

market

quotations are

not

readily

available

or

deemed

unreliable

are

valued

at

fair

value

as

determined

in

good

faith

by

the

Valuation

Designee.

The

Valuation

Designee

has

adopted

methodologies

for

determining

the

fair

value

of

investments

for

which

market

quotations

are

not

readily

available

or

deemed

unreliable,

including

the

use

of

other

pricing

sources.

Factors

used

in

determining

fair

value

vary

by

type

of

investment

and

may

include

market

or

investment

specific

considerations.

The

Valuation

Designee typically

will

afford

greatest

weight

to

actual

prices

in

arm’s

length

transactions,

to

the

extent

they

represent

orderly

transactions

between

market

participants,

transaction

information

can

be

reliably

obtained,

and

prices

are

deemed

representative

of

fair

value.

However,

the

Valuation

Designee may

also

consider

other

valuation

methods

such

as

market-based

valuation

multiples;

a

discount

or

premium

from

market

value

of

a

similar,

freely

traded

security

of

the

same

issuer;

discounted

cash

T.

ROWE

PRICE

Health

Sciences

Fund

38

flows;

yield

to

maturity;

or

some

combination.

Fair

value

determinations

are

reviewed

on

a

regular

basis.

Because

any

fair

value

determination

involves

a

significant

amount

of

judgment,

there

is

a

degree

of

subjectivity

inherent

in

such

pricing

decisions. Fair

value

prices

determined

by

the

Valuation

Designee could

differ

from

those

of

other

market

participants,

and

it

is

possible

that

the

fair

value

determined

for

a

security

may

be

materially

different

from

the

value

that

could

be

realized

upon

the

sale

of

that

security.

Valuation

Inputs

  The

following

table

summarizes

the

fund’s

financial

instruments,

based

on

the

inputs

used

to

determine

their

fair

values

on

December

31,

2022

(for

further

detail

by

category,

please

refer

to

the

accompanying

Portfolio

of

Investments):

Following

is

a

reconciliation

of

the

fund’s

Level

3

holdings

for

the

year ended

December

31,

2022.

Gain

(loss)

reflects

both

realized

and

change

in

unrealized

gain/

loss

on

Level

3

holdings

during

the

period,

if

any,

and

is

included

on

the

accompanying

Statement

of

Operations.

The

change

in

unrealized

gain/loss

on

Level

3

instruments

held

at

December

31,

2022,

totaled $(54,912,000) for

the

year ended

December

31,

2022.

o

In

accordance

with

GAAP,

the

following

table

provides

quantitative

information

about

significant

unobservable

inputs

used

to

determine

the

fair

valuations

of

the

fund’s

Level

3

assets,

by

class

of

financial

instrument.

Because

the

Valuation

Designee

considers

($000s)

Level

1

Level

2

Level

3

Total

Value

Assets

Common

Stocks

$

14,720,053‌

$

449,703‌

$

60,839‌

$

15,230,595‌

Convertible

Preferred

Stocks

—‌

—‌

714,986‌

714,986‌

Preferred

Stocks

—‌

94,798‌

—‌

94,798‌

Short-Term

Investments

158,976‌

—‌

—‌

158,976‌

Total

$

14,879,029‌

$

544,501‌

$

775,825‌

$

16,199,355‌

($000s)

Beginning

Balance

12/31/21

Gain

(Loss)

During

Period

Total

Purchases

Total

Sales

Ending

Balance

12/31/22

Investment

in

Securities

Common

Stocks

$

58,155‌

$

(20,956‌)

$

32,547‌

$

(8,907‌)

$

60,839‌

Convertible

Preferred

Stocks

706,485‌

2,198‌

91,063‌

(84,760‌)

714,986‌

Total

$

764,640‌

$

(18,758‌)

$

123,610‌

$

(93,667‌)

$

775,825‌

T.

ROWE

PRICE

Health

Sciences

Fund

39

a

wide

variety

of

factors

and

inputs,

both

observable

and

unobservable,

in

determining

fair

values,

the

unobservable

inputs

presented

do

not

reflect

all

inputs

significant

to

the

fair

value

determination.

Investments

in

Securities

Value

(000s)

Valuation

Technique(s)+

Significant

Unobservable

Input(s)

Value

or

Range

of

Input(s)

Weighted

Average

of

Input(s)*

Impact

to

Valuation

from

an

Increase

in

Input**

Common

Stocks

$

60,839‌

Recent

comparable

transaction

price(s)

—#

—#

—#

—#

Discount

for

uncertainty

5%

-

78%

55%

Decrease

Market

comparable

Enterprise

value

to

sales

multiple

2.8x

2.8x

Increase

Enterprise

value

to

gross

profit

multiple

6.0x

6.0x

Increase

Probability

for

alternate

outcome

20%

-

40%

30%

Decrease

Discount

for

lack

of

marketability

10%

10%

Decrease

Expected

present

value

Discount

rate

for

cost

of

equity

12%

-

25%

14%

Decrease

Discount

for

regulatory

uncertainty

29%

-

100%

29%

Decrease

Convertible

Preferred

Stocks

$

714,986‌

Recent

comparable

transaction

price(s)

—#

—#

—#

—#

T.

ROWE

PRICE

Health

Sciences

Fund

40

Investments

in

Securities

Value

(000s)

Valuation

Technique(s)+

Significant

Unobservable

Input(s)

Value

or

Range

of

Input(s)

Weighted

Average

of

Input(s)*

Impact

to

Valuation

from

an

Increase

in

Input**

Premium

for

cumulative

preferred

dividend

rights

3%

-

8%

4%

Increase

Discount

for

cumulative

preferred

dividend

rights

2%

2%

Decrease

Market

comparable

Enterprise

value

to

sales

multiple

2.5x

–

11.7x

4.9x

Increase

Sales

growth

rate

(58%)

-

266%

13%

Increase

Enterprise

value

to

gross

profit

multiple

8.5x

–

10.2x

9.4x

Increase

Gross

profit

growth

rate

29%

29%

Increase

Discount

rate

for

cost

of

capital

30%

30%

Decrease

Discount

for

lack

of

marketability

10%

10%

Decrease

Estimated

liquidation

value

Discount

for

lack

of

collectability

100%

100%

Decrease

T.

ROWE

PRICE

Health

Sciences

Fund

41

+

Valuation

techniques

may

change

in

order

to

reflect the

Valuation

Designee’s

judgment

of

current

market

participant

assumptions. 

*

Unobservable

inputs

were

weighted

by

the

relative

fair

value

of

the

instruments.

**

Represents

the

directional

change

in

the

fair

value

of

the

Level

3

investment(s)

that

would

have

resulted

from

an

increase

in

the

corresponding

input

at

period

end.

A

decrease

in

the

unobservable

input

would

have

had

the

opposite

effect.

Significant

increases

and

decreases

in

these

inputs

in

isolation

could

result

in

significantly

higher

or

lower

fair

value

measurements.

#

No

quantitative

unobservable

inputs

significant

to

the

valuation

technique

were

created

by

the

Valuation

Designee.

NOTE

3

-

OTHER

INVESTMENT

TRANSACTIONS 

Consistent

with

its

investment

objective,

the

fund

engages

in

the

following

practices

to

manage

exposure

to

certain

risks

and/or

to

enhance

performance.

The

investment

objective,

policies,

program,

and

risk

factors

of

the

fund

are

described

more

fully

in

the

fund’s

prospectus

and

Statement

of

Additional

Information.

Restricted

Securities

 The

fund

invests

in

securities

that

are

subject

to

legal

or

contractual

restrictions

on

resale.

Prompt

sale

of

such

securities

at

an

acceptable

price

may

be

difficult

and

may

involve

substantial

delays

and

additional

costs.

Private

Investments

Issued

by

Special

Purpose

Acquisition

Companies

Special purpose

acquisition

companies

(SPACs)

are

shell

companies

that

have

no

operations

but

are

formed

to

raise

capital

with

the

intention

of

merging

with

or

acquiring

a

company

with

the

proceeds

of

the

SPAC’s

initial

public

offering

(IPO).

The

fund

may

enter

into

a

contingent

commitment

with

a

SPAC

to

purchase

private

investments

in

public

equity

(PIPE)

if

and

when

the

SPAC

completes

its

merger

or

acquisition.

The

fund

maintains

liquid

assets

sufficient

to

settle

its

commitment

to

purchase

the

PIPE.

However,

if

the

commitment

expires,

then

no

shares

are

purchased.

Purchased

PIPE

shares

will

be

restricted

from

trading

until

the

registration

statement

for

the

shares

is

declared

effective.

Upon

registration,

the

shares

can

be

freely

sold;

however,

in

certain

circumstances,

the

issuer

may

have

the

right

to

temporarily

suspend

trading

of

the

shares

in

the

first

year

after

the

merger

or

acquisition.

The

securities

issued

by

a

SPAC

may

be

considered

illiquid,

more

difficult

to

value,

and/or

be

subject

to

restrictions

on

resale.

Other 

Purchases

and

sales

of

portfolio

securities

other

than

short-term securities

aggregated $4,752,095,000 and

$5,816,314,000,

respectively,

for

the

year ended

December

31,

2022.

T.

ROWE

PRICE

Health

Sciences

Fund

42

NOTE

4

-

FEDERAL

INCOME

TAXES

Generally,

no

provision

for

federal

income

taxes

is

required

since

the

fund

intends

to

continue

to

qualify

as

a

regulated

investment

company

under

Subchapter

M

of

the

Internal

Revenue

Code

and

distribute

to

shareholders

all

of

its

taxable

income

and

gains.

Distributions

determined

in

accordance

with

federal

income

tax

regulations

may

differ

in

amount

or

character

from

net

investment

income

and

realized

gains

for

financial

reporting

purposes.

The fund

files

U.S.

federal,

state,

and

local

tax

returns

as

required. The

fund’s

tax

returns

are

subject

to

examination

by

the

relevant

tax

authorities

until

expiration

of

the

applicable

statute

of

limitations,

which

is

generally

three

years

after

the

filing

of

the

tax

return

but

which

can

be

extended

to

six

years

in

certain

circumstances.

Tax

returns

for

open

years

have

incorporated

no

uncertain

tax

positions

that

require

a

provision

for

income

taxes.

Capital

accounts

within

the

financial

reporting

records

are

adjusted

for

permanent

book/tax

differences

to

reflect

tax

character

but

are

not

adjusted

for

temporary

differences.

The

permanent

book/tax

adjustments,

if

any,

have

no

impact

on

results

of

operations

or

net

assets.

The

permanent

book/tax

adjustments

relate

primarily

to

the

current

net

operating

loss.

The

tax

character

of

distributions

paid

for

the

periods

presented

was

as

follows:

At

December

31,

2022,

the

tax-basis

cost

of

investments

(including

derivatives,

if

any)

and

gross

unrealized

appreciation

and

depreciation

were

as

follows:

($000s)

December

31,

2022

December

31,

2021

Ordinary

income

(including

short-term

capital

gains,

if

any)

$

805‌

$

301,547‌

Long-term

capital

gain

281,770‌

1,062,596‌

Total

distributions

$

282,575‌

$

1,364,143‌

($000s)

Cost

of

investments

$

8,569,479‌

Unrealized

appreciation

$

8,439,370‌

Unrealized

depreciation

(809,411‌)

Net

unrealized

appreciation

(depreciation)

$

7,629,959‌

T.

ROWE

PRICE

Health

Sciences

Fund

43

At

December

31,

2022,

the

tax-basis

components

of

accumulated

net

earnings

(loss)

were

as

follows:

Temporary

differences

between

book-basis

and

tax-basis

components

of

total

distributable

earnings

(loss)

arise

when

certain

items

of

income,

gain,

or

loss

are

recognized

in

different

periods

for

financial

statement

purposes

versus

for

tax

purposes;

these

differences

will

reverse

in

a

subsequent

reporting

period.

The

temporary

differences

relate

primarily

to

the

deferral

of

losses

from

wash

sales

and

the

realization

of

gains/losses

on

passive

foreign

investment

companies.

The

loss

carryforwards

and

deferrals

primarily

relate

to

late-year

ordinary

loss

deferrals. The

fund

has

elected

to

defer

certain

losses

to

the

first

day

of

the

following

fiscal

year

for

late-year

ordinary

loss

deferrals.

NOTE

5

-

FOREIGN  TAXES

The

fund

is

subject

to

foreign

income

taxes

imposed

by

certain

countries

in

which

it

invests.

Additionally,

capital

gains

realized

upon

disposition

of

securities

issued

in

or

by

certain

foreign

countries

are

subject

to

capital

gains

tax

imposed

by

those

countries.

All

taxes

are

computed

in

accordance

with

the

applicable

foreign

tax

law,

and,

to

the

extent

permitted,

capital

losses

are

used

to

offset

capital

gains.

Taxes

attributable

to

income

are

accrued

by

the

fund

as

a

reduction

of

income.

Current

and

deferred

tax

expense

attributable

to

capital

gains

is

reflected

as

a

component

of

realized

or

change

in

unrealized

gain/loss

on

securities

in

the

accompanying

financial

statements.

To

the

extent

that

the

fund

has

country

specific

capital

loss

carryforwards,

such

carryforwards

are

applied

against

net

unrealized

gains

when

determining

the

deferred

tax

liability.

Any

deferred

tax

liability

incurred

by

the

fund

is

included

in

either

Other

liabilities

or

Deferred

tax

liability

on

the

accompanying

Statement

of

Assets

and

Liabilities.

($000s)

Undistributed

long-term

capital

gain

$

56,915‌

Net

unrealized

appreciation

(depreciation)

7,629,959‌

Loss

carryforwards

and

deferrals

(6,647‌)

Total

distributable

earnings

(loss)

$

7,680,227‌

T.

ROWE

PRICE

Health

Sciences

Fund

44

NOTE

6

-

RELATED

PARTY

TRANSACTIONS

The

fund

is

managed

by

T.

Rowe

Price

Associates,

Inc.

(Price

Associates),

a

wholly

owned

subsidiary

of

T.

Rowe

Price

Group,

Inc.

(Price

Group). The

investment

management

agreement

between

the

fund

and

Price

Associates

provides

for

an

annual

investment

management

fee

that

consists

of

an

individual

fund

fee

and

a

group

fee;

management

fees

are

computed

daily

and

paid

monthly.

The

investment

management

agreement

provides

for

an

individual

fund

fee

equal

to

0.35%

of

the fund’s

average

daily

net

assets.

The

group

fee

rate

is

calculated

based

on

the

combined

net

assets

of

certain

mutual

funds

sponsored

by

Price

Associates

(the

group)

applied

to

a

graduated

fee

schedule,

with

rates

ranging

from

0.48%

for

the

first

$1

billion

of

assets

to

0.260%

for

assets

in

excess

of

$845

billion.

The

fund’s

group

fee

is

determined

by

applying

the

group

fee

rate

to

the

fund’s

average

daily

net

assets.

At December

31,

2022,

the

effective

annual

group

fee

rate

was

0.29%. Effective

May

1,

2021,

Price

Associates

has

contractually

agreed,

at

least

through

April

30,

2023,

to

waive

a

portion

of

its

management

fee

so

that

an

individual

fund

fee

of 0.2975%

is

applied

to

the

fund’s

average

daily

net

assets

that

are

equal

to

or

greater

than $25 billion.

Thereafter,

this

agreement

will

automatically

renew

for

one-year

terms

unless

terminated

by

the

fund’s

Board.

Any

fees

waived

under

this

agreement

are

not

subject

to

reimbursement

to

Price

Associates

by

the

fund. No

management

fees

were

waived

under

this

arrangement

for

the

year ended

December

31,

2022. 

The

I

Class

is

subject

to

an

operating

expense

limitation

(I

Class

Limit)

pursuant

to

which

Price

Associates

is

contractually

required

to

pay

all

operating

expenses

of

the

I

Class,

excluding

management

fees;

interest;

expenses

related

to

borrowings,

taxes,

and

brokerage; non-recurring,

extraordinary expenses; and

acquired

fund

fees

and

expenses, to

the

extent

such

operating

expenses,

on

an

annualized

basis,

exceed

the

I

Class

Limit. This

agreement

will

continue

through

the

expense

limitation

date

indicated

in

the

table

below,

and

may

be

renewed,

revised,

or

revoked

only

with

approval

of

the

fund’s

Board.

The

I

Class

is

required

to

repay

Price

Associates

for

expenses

previously

paid

to

the

extent

the

class’s

net

assets

grow

or

expenses

decline

sufficiently

to

allow

repayment

without

causing

the

class’s

operating

expenses

(after

the

repayment

is

taken

into

account)

to

exceed

the

lesser

of:

(1)

the

I

Class

Limit

in

place

at

the

time

such

amounts

were

paid;

or

(2)

the

current

I

Class

Limit.

However,

no

repayment

will

be

made

more

than

three

years

after

the

date

of

a

payment

or

waiver.

T.

ROWE

PRICE

Health

Sciences

Fund

45

In

addition,

the

fund

has

entered

into

service

agreements

with

Price

Associates

and

two

wholly

owned

subsidiaries

of

Price

Associates,

each

an

affiliate

of

the

fund

(collectively,

Price).

Price

Associates

provides

certain

accounting

and

administrative

services

to

the

fund.

T.

Rowe

Price

Services,

Inc.

provides

shareholder

and

administrative

services

in

its

capacity

as

the

fund’s

transfer

and

dividend-disbursing

agent.

T.

Rowe

Price

Retirement

Plan

Services,

Inc.

provides

subaccounting

and

recordkeeping

services

for

certain

retirement

accounts

invested

in

the

Investor

Class.

For

the

year ended

December

31,

2022,

expenses

incurred

pursuant

to

these

service

agreements

were

$102,000 for

Price

Associates;

$6,898,000 for

T.

Rowe

Price

Services,

Inc.;

and

$605,000 for

T.

Rowe

Price

Retirement

Plan

Services,

Inc.

All

amounts

due

to

and

due

from

Price,

exclusive

of

investment

management

fees

payable,

are

presented

net

on

the

accompanying

Statement

of

Assets

and

Liabilities.

Additionally,

the

fund

is

one

of

several

mutual

funds

in

which

certain

college

savings

plans

managed

by

Price

Associates may

invest.

As

approved

by

the

fund’s

Board

of

Directors,

shareholder

servicing

costs

associated

with

each

college

savings

plan

are

borne

by

the

fund

in

proportion

to

the

average

daily

value

of

its

shares

owned

by

the

college

savings

plan.

Price

has

agreed

to waive/reimburse

shareholder

servicing

costs in

excess

of

0.05%

of

the

fund’s

average

daily

value

of

its

shares

owned

by

the

college

savings

plan.

Any

amounts

waived/paid

by

Price

under

this

voluntary

agreement

are

not

subject

to

repayment

by

the

fund.

Price

may

amend

or

terminate

this

voluntary

arrangement

at

any

time

without

prior

notice.

For

the

year ended

December

31,

2022,

the

fund

was

charged $112,000 for

shareholder

servicing

costs

related

to

the

college

savings

plans, of

which

$82,000

was

for

services

provided

by

Price.

All

amounts

due

to

and

due

from

Price,

exclusive

of

investment

management

fees

payable,

are

presented

net

on

the

accompanying

Statement

of

Assets

and

Liabilities. At

December

31,

2022,

approximately less

than

1%

of

the

outstanding

shares

of

the

I

Class

were

held

by

the

college

savings

plans.

The fund

may

invest

its

cash

reserves

in

certain

open-end

management

investment

companies

managed

by

Price

Associates

and

considered

affiliates

of

the

fund:

the

T.

Rowe

Price

Government

Reserve

Fund

or

the

T.

Rowe

Price

Treasury

Reserve

Fund,

organized

as

money

market

funds

(together,

the

Price

Reserve

Funds).

The

Price

Reserve

Funds

are

offered

as

short-term

investment

options

to

mutual

funds,

trusts,

and

other

I

Class

Expense

limitation/I

Class

Limit

0.05%

Expense

limitation

date

04/30/24

(Waived)/repaid

during

the

period

($000s)

$—

T.

ROWE

PRICE

Health

Sciences

Fund

46

accounts

managed

by

Price

Associates

or

its

affiliates

and

are

not

available

for

direct

purchase

by

members

of

the

public.

Cash

collateral

from

securities

lending,

if

any,

is

invested

in

the

T.

Rowe

Price

Government

Reserve Fund. The

Price

Reserve

Funds

pay

no

investment

management

fees.

As

of

December

31,

2022,

T.

Rowe

Price

Group,

Inc.,

or

its

wholly

owned

subsidiaries,

owned

140,512

shares

of

the

I

Class,

representing

less

than

1%

of

the

I

Class's

net

assets. 

The

fund may

participate

in

securities

purchase

and

sale

transactions

with

other

funds

or

accounts

advised

by

Price

Associates

(cross

trades),

in

accordance

with

procedures

adopted

by the

fund’s

Board

and

Securities

and

Exchange

Commission

rules,

which

require,

among

other

things,

that

such

purchase

and

sale

cross

trades

be

effected

at

the

independent

current

market

price

of

the

security.

During

the

year ended

December

31,

2022,

the

fund

had

no

purchases

or

sales

cross

trades

with

other

funds

or

accounts

advised

by

Price

Associates.

Price

Associates

has

voluntarily

agreed

to

reimburse

the

fund

from

its

own

resources

on

a

monthly

basis

for

the

cost

of

investment

research

embedded

in

the

cost

of

the

fund’s

securities

trades.

This

agreement

may

be

rescinded

at

any

time.

For

the

year ended

December

31,

2022,

this

reimbursement

amounted

to

$284,000,

which

is

included

in

Net

realized

gain

(loss)

on

Securities

in

the

Statement

of

Operations.

NOTE

7

-

OTHER

MATTERS

Unpredictable

events

such

as

environmental

or

natural

disasters,

war,

terrorism,

pandemics,

outbreaks

of

infectious

diseases,

and

similar

public

health

threats

may

significantly

affect

the

economy

and

the

markets

and

issuers

in

which

the fund

invests.

Certain

events

may

cause

instability

across

global

markets,

including

reduced

liquidity

and

disruptions

in

trading

markets,

while

some

events

may

affect

certain

geographic

regions,

countries,

sectors,

and

industries

more

significantly

than

others,

and

exacerbate

other

pre-existing

political,

social,

and

economic

risks.

Since

2020,

a

novel

strain

of

coronavirus

(COVID-19)

has

resulted

in

disruptions

to

global

business

activity

and

caused

significant

volatility

and

declines

in

global

financial

markets.

In

February

2022,

Russian

forces

entered

Ukraine

and

commenced

an

armed

conflict

leading

to

economic

sanctions

being

imposed

on

Russia

and

certain

of

its

citizens,

creating

impacts

on

Russian-related

stocks

and

debt

and

greater

volatility

in

global

markets.

T.

ROWE

PRICE

Health

Sciences

Fund

47

These

are

recent

examples

of

global

events

which

may

have

a

negative

impact

on

the

values

of

certain

portfolio

holdings

or

the

fund’s

overall

performance.

Management

is

actively

monitoring

the

risks

and

financial

impacts

arising

from

these

events.

T.

ROWE

PRICE

Health

Sciences

Fund

48

REPORT

OF

INDEPENDENT

REGISTERED

PUBLIC

ACCOUNTING

FIRM

To

the

Board

of

Directors

and

Shareholders

of

T.

Rowe

Price

Health

Sciences

Fund,

Inc.

Opinion

on

the

Financial

Statements

We

have

audited

the

accompanying

statement

of

assets

and

liabilities,

including

the

portfolio

of

investments,

of

T.

Rowe

Price

Health

Sciences

Fund,

Inc.

(the

"Fund")

as

of

December

31,

2022,

the

related

statement

of

operations

for

the

year

ended

December

31,

2022,

the

statement

of

changes

in

net

assets

for

each

of

the

two

years

in

the

period

ended

December

31,

2022,

including

the

related

notes,

and

the

financial

highlights

for

each

of

the

five

years

in

the

period

ended

December

31,

2022

(collectively

referred

to

as

the

“financial

statements”).

In

our

opinion,

the

financial

statements

present

fairly,

in

all

material

respects,

the

financial

position

of

the

Fund

as

of

December

31,

2022,

the

results

of

its

operations

for

the

year

then

ended,

the

changes

in

its

net

assets

for

each

of

the

two

years

in

the

period

ended

December

31,

2022

and

the

financial

highlights

for

each

of

the

five

years

in

the

period

ended

December

31,

2022

in

conformity

with

accounting

principles

generally

accepted

in

the

United

States

of

America.

Basis

for

Opinion

These

financial

statements

are

the

responsibility

of

the

Fund’s

management.

Our

responsibility

is

to

express

an

opinion

on

the

Fund’s

financial

statements

based

on

our

audits.

We

are

a

public

accounting

firm

registered

with

the

Public

Company

Accounting

Oversight

Board

(United

States)

(PCAOB)

and

are

required

to

be

independent

with

respect

to

the

Fund

in

accordance

with

the

U.S.

federal

securities

laws

and

the

applicable

rules

and

regulations

of

the

Securities

and

Exchange

Commission

and

the

PCAOB.

We

conducted

our

audits

of

these

financial

statements

in

accordance

with

the

standards

of

the

PCAOB.

Those

standards

require

that

we

plan

and

perform

the

audit

to

obtain

reasonable

assurance

about

whether

the

financial

statements

are

free

of

material

misstatement,

whether

due

to

error

or

fraud.

T.

ROWE

PRICE

Health

Sciences

Fund

49

Our

audits

included

performing

procedures

to

assess

the

risks

of

material

misstatement

of

the

financial

statements,

whether

due

to

error

or

fraud,

and

performing

procedures

that

respond

to

those

risks.

Such

procedures

included

examining,

on

a

test

basis,

evidence

regarding

the

amounts

and

disclosures

in

the

financial

statements.

Our

audits

also

included

evaluating

the

accounting

principles

used

and

significant

estimates

made

by

management,

as

well

as

evaluating

the

overall

presentation

of

the

financial

statements.

Our

procedures

included

confirmation

of

securities

owned

as

of

December

31,

2022

by

correspondence

with

the

custodians,

transfer

agent

and

brokers;

when

replies

were

not

received

from

brokers,

we

performed

other

auditing

procedures.

We

believe

that

our

audits

provide

a

reasonable

basis

for

our

opinion.   

PricewaterhouseCoopers

LLP

Baltimore,

Maryland

February

16,

2023

We

have

served

as

the

auditor

of

one

or

more

investment

companies

in

the

T.

Rowe

Price

group

of

investment

companies

since

1973.

REPORT

OF

INDEPENDENT

REGISTERED

PUBLIC

ACCOUNTING

FIRM

(continued)

T.

ROWE

PRICE

Health

Sciences

Fund

50

TAX

INFORMATION

(UNAUDITED)

FOR

THE

TAX

YEAR

ENDED 12/31/22

We

are

providing

this

information

as

required

by

the

Internal

Revenue

Code.

The

amounts

shown

may

differ

from

those

elsewhere

in

this

report

because

of

differences

between

tax

and

financial

reporting

requirements.

The

fund’s

distributions

to

shareholders

included:

$805,000 from

short-term

capital

gains 

$281,826,000 from

long-term

capital

gains,

subject

to

a

long-term

capital

gains

tax

rate

of

not

greater

than

20%

T.

ROWE

PRICE

Health

Sciences

Fund

51

INFORMATION

ON

PROXY

VOTING

POLICIES,

PROCEDURES,

AND

RECORDS

A

description

of

the

policies

and

procedures

used

by

T.

Rowe

Price

funds

to

determine

how

to

vote

proxies

relating

to

portfolio

securities

is

available

in

each

fund’s

Statement

of

Additional

Information.

You

may

request

this

document

by

calling

1-800-225-5132

or

by

accessing

the

SEC’s

website,

sec.gov.

The

description

of

our

proxy

voting

policies

and

procedures

is

also

available

on

our

corporate

website.

To

access

it,

please

visit

the

following

Web

page:

https://www.troweprice.com/corporate/us/en/utility/policies.html

Scroll

down

to

the

section

near

the

bottom

of

the

page

that

says,

“Proxy

Voting

Guidelines.”

Click

on

the

links

in

the

shaded

box.

Each

fund’s

most

recent

annual

proxy

voting

record

is

available

on

our

website

and

through

the

SEC’s

website.

To

access

it

through

T.

Rowe

Price,

visit

the

website

location

shown

above,

and

scroll

down

to

the

section

near

the

bottom

of

the

page

that

says,

“Proxy

Voting

Records.”

Click

on

the

Proxy

Voting

Records

link

in

the

shaded

box.

HOW

TO

OBTAIN

QUARTERLY

PORTFOLIO

HOLDINGS

The

fund

files

a

complete

schedule

of

portfolio

holdings

with

the

Securities

and

Exchange

Commission

(SEC)

for

the

first

and

third

quarters

of

each

fiscal

year

as

an

exhibit

to

its

reports

on

Form

N-PORT.

The

fund’s

reports

on

Form

N-PORT

are

available

electronically

on

the

SEC’s

website

(sec.gov).

In

addition,

most

T.

Rowe

Price

funds

disclose

their

first

and

third

fiscal

quarter-end

holdings

on

troweprice.com

.

T.

ROWE

PRICE

Health

Sciences

Fund

52

Liquidity

Risk

Management

Program

In

accordance

with

Rule

22e-4

(Liquidity

Rule)

under

the

Investment

Company

Act

of

1940,

as

amended,

the

fund

has

established

a

liquidity

risk

management

program

(Liquidity

Program)

reasonably

designed

to

assess

and

manage

the

fund’s

liquidity

risk,

which

generally

represents

the

risk

that

the

fund

would

not

be

able

to

meet

redemption

requests

without

significant

dilution

of

remaining

investors’

interests

in

the

fund.

The

fund’s

Board

of

Directors

(Board)

has

appointed

the

fund’s

investment

adviser,

T.

Rowe

Price

Associates,

Inc.

(Adviser),

as

the

administrator

of

the

Liquidity

Program.

As

administrator,

the

Adviser

is

responsible

for

overseeing

the

day-to-day

operations

of

the

Liquidity

Program

and,

among

other

things,

is

responsible

for

assessing,

managing,

and

reviewing

with

the

Board

at

least

annually

the

liquidity

risk

of

each

T.

Rowe

Price

fund.

The

Adviser

has

delegated

oversight

of

the

Liquidity

Program

to

a

Liquidity

Risk

Committee

(LRC),

which

is

a

cross-functional

committee

composed

of

personnel

from

multiple

departments

within

the

Adviser.

The

Liquidity Program’s principal

objectives

include

supporting

the T.

Rowe

Price

funds’ compliance

with

limits

on

investments

in

illiquid

assets

and

mitigating

the

risk

that

the

fund

will

be

unable to timely

meet

its

redemption

obligations. The

Liquidity

Program

also

includes

a

number

of

elements

that

support

the

management

and

assessment

of

liquidity

risk,

including

an

annual

assessment

of

factors

that

influence

the fund’s liquidity

and

the

periodic

classification

and

reclassification

of

a

fund’s

investments

into

categories

that

reflect

the

LRC’s

assessment

of

their

relative

liquidity

under

current

market

conditions.

Under

the

Liquidity

Program,

every

investment

held

by

the

fund

is

classified

at

least

monthly

into

one

of

four

liquidity

categories

based

on

estimations

of

the

investment’s

ability

to

be

sold

during

designated

time

frames

in

current

market

conditions

without

significantly

changing

the

investment’s

market

value.

As

required

by

the

Liquidity

Rule,

at

a

meeting

held

on

July

25,

2022,

the

Board

was

presented

with

an

annual

assessment

prepared

by

the

LRC,

on

behalf

of

the

Adviser,

that

addressed

the

operation

of

the

Liquidity

Program

and

assessed

its

adequacy

and

effectiveness

of

implementation,

including

any

material

changes

to

the

Liquidity

Program

and

the

determination

of

each

fund’s

Highly

Liquid

Investment

Minimum

(HLIM).

The

annual

assessment

included

consideration

of

the

following

factors,

as

applicable:

the

fund’s

investment

strategy

and

liquidity

of

portfolio

investments

during

normal

and

reasonably

foreseeable

stressed

conditions,

including

whether

the

investment

strategy

is

appropriate

for

an

open-end

fund,

the

extent

to

which

the

strategy

involves

a

relatively

concentrated

portfolio

or

large

positions

in

particular

issuers,

and

the

use

of

borrowings

for

investment

purposes

and

derivatives;

short-term

and

long-term

cash

flow

projections

covering

both

normal

and

reasonably

foreseeable

stressed

conditions;

and

holdings

of

cash

and

cash

equivalents,

as

well

as

available

borrowing

arrangements.

T.

ROWE

PRICE

Health

Sciences

Fund

53

For

the

fund

and

other

T.

Rowe

Price

funds,

the

annual

assessment

incorporated

a

report

related

to

a

fund’s

holdings,

shareholder

and

portfolio

concentration,

any

borrowings

during

the

period,

cash

flow

projections,

and

other

relevant

data

for

the

period

of

April

1,

2021,

through

March

31,

2022.

The

report

described

the

methodology

for

classifying

a

fund’s

investments

(including

any

derivative

transactions)

into

one

of

four

liquidity

categories,

as

well

as

the

percentage

of

a

fund’s

investments

assigned

to

each

category.

It

also

explained

the

methodology

for

establishing

a

fund’s

HLIM

and

noted

that

the

LRC

reviews

the

HLIM

assigned

to

each

fund

no

less

frequently

than

annually.

During

the

period

covered

by

the

annual

assessment,

the

LRC

has

concluded,

and

reported

to

the

Board,

that

the

Liquidity

Program

continues

to

operate

adequately

and

effectively

and

is

reasonably

designed

to

assess

and

manage

the

fund’s

liquidity

risk.

T.

ROWE

PRICE

Health

Sciences

Fund

54

ABOUT

THE

FUND'S

DIRECTORS

AND

OFFICERS

Your

fund

is

overseen

by

a

Board

of

Directors

(Board)

that

meets

regularly

to

review

a

wide

variety

of

matters

affecting

or

potentially

affecting

the

fund,

including

performance,

investment

programs,

compliance

matters,

advisory

fees

and

expenses,

service

providers,

and

business

and

regulatory

affairs.

The

Board

elects

the

fund’s

officers,

who

are

listed

in

the

final

table.

The

directors

who

are

also

employees

or

officers

of

T.

Rowe

Price

are

considered

to

be

“interested”

directors

as

defined

in

Section

2(a)(19)

of

the

1940

Act

because

of

their

relationships

with

T.

Rowe

Price

and

its

affiliates.

The

business

address

of

each

director

and

officer

is

100

East

Pratt

Street,

Baltimore,

Maryland

21202.

The

Statement

of

Additional

Information

includes

additional

information

about

the

fund

directors

and

is

available

without

charge

by

calling

a

T.

Rowe

Price

representative

at

1-800-638-5660.

INDEPENDENT

DIRECTORS

(a)

Name

(Year

of

Birth)

Year

Elected

[Number

of

T.

Rowe

Price

Portfolios

Overseen]

Principal

Occupation(s)

and

Directorships

of

Public

Companies

and

Other

Investment

Companies

During

the

Past

Five

Years

Teresa

Bryce

Bazemore

(1959)

2018

[205]

President

and

Chief

Executive

Officer,

Federal

Home

Loan

Bank

of

San

Francisco

(2021

to

present);

President,

Radian

Guaranty

(2008

to

2017);

Chief

Executive

Officer,

Bazemore

Consulting

LLC

(2018

to

2021);

Director,

Chimera

Investment

Corporation

(2017

to

2021);

Director,

First

Industrial

Realty

Trust

(2020

to

present);

Director,

Federal

Home

Loan

Bank

of

Pittsburgh

(2017

to

2019)

Ronald

J.

Daniels

(b)

(1959)

2018

[0]

President,

The

Johns

Hopkins

University

and

Professor,

Political

Science

Department,

The

Johns

Hopkins

University

(2009

to

present);

Director,

Lyndhurst

Holdings

(2015

to

present);

Director,

BridgeBio

Pharma,

Inc.

(2020

to

present)

Bruce

W.

Duncan

(1951)

2013

[205]

President,

Chief

Executive

Officer,

and

Director,

CyrusOne,

Inc.

(2020

to

2021);

Chief

Executive

Officer

and

Director

(2009

to

2016),

Chair

of

the

Board

(2016

to

2020),

and

President

(2009

to

2016),

First

Industrial

Realty

Trust,

owner

and

operator

of

industrial

properties;

Chair

of

the

Board

(2005

to

2016)

and

Director

(1999

to

2016),

Starwood

Hotels

&

Resorts,

a

hotel

and

leisure

company;

Member,

Investment

Company

Institute

Board

of

Governors

(2017

to

2019);

Member,

Independent

Directors

Council

Governing

Board

(2017

to

2019);

Senior

Advisor,

KKR

(2018

to

present);

Director,

Boston

Properties

(2016

to

present);

Director,

Marriott

International,

Inc.

(2016

to

2020)

Robert

J.

Gerrard,

Jr.

(1952)

2012

[205]

Advisory

Board

Member,

Pipeline

Crisis/Winning

Strategies,

a

collaborative

working

to

improve

opportunities

for

young

African

Americans

(1997

to

2016);

Chair

of

the

Board,

all

funds

(July

2018

to

present)

T.

ROWE

PRICE

Health

Sciences

Fund

55

INTERESTED  DIRECTORS

(a)

Name

(Year

of

Birth)

Year

Elected

[Number

of

T.

Rowe

Price

Portfolios

Overseen]

Principal

Occupation(s)

and

Directorships

of

Public

Companies

and

Other

Investment

Companies

During

the

Past

Five

Years

Paul

F.

McBride

(1956)

2013

[205]

Advisory

Board

Member,

Vizzia

Technologies

(2015

to

present);

Board

Member,

Dunbar

Armored

(2012

to

2018)

Kellye

L.

Walker

(c)

(1966)

2021

[205]

Executive

Vice

President

and

Chief

Legal

Officer,

Eastman

Chemical

Company

(April

2020

to

present);

Executive

Vice

President

and

Chief

Legal

Officer,

Huntington

Ingalls

Industries,

Inc.

(January

2015

to

March

2020);

Director,

Lincoln

Electric

Company

(October

2020

to

present)

(a)

All

information

about

the

independent

directors

was

current

as

of

December

31,

2021,

unless

otherwise

indicated,

except

for

the

number

of

portfolios

overseen,

which

is

current

as

of

the

date

of

this

report.

(b)

Effective

April

27,

2022,

Mr.

Daniels

resigned

from

his

role

as

an

independent

director

of

the

Price

Funds.

(c)

Effective

November

8,

2021,

Ms.

Walker

was

appointed

as

an

independent

director

of

the

Price

Funds.

Name

(Year

of

Birth)

Year

Elected

[Number

of

T.

Rowe

Price

Portfolios

Overseen]

Principal

Occupation(s)

and

Directorships

of

Public

Companies

and

Other

Investment

Companies

During

the

Past

Five

Years

David

Oestreicher

(1967)

2018

[205]

Director,

Vice

President,

and

Secretary,

T.

Rowe

Price,

T.

Rowe

Price

Investment

Services,

Inc.,

T.

Rowe

Price

Retirement

Plan

Services,

Inc.,

and

T.

Rowe

Price

Services,

Inc.;

Director

and

Secretary,

T.

Rowe

Price

Investment

Management,

Inc.

(Price

Investment

Management);

Vice

President

and

Secretary,

T.

Rowe

Price

International

(Price

International);

Vice

President,

T.

Rowe

Price

Hong

Kong

(Price

Hong

Kong),

T. Rowe

Price

Japan

(Price

Japan),

and

T.

Rowe

Price

Singapore

(Price

Singapore);

General

Counsel,

Vice

President,

and

Secretary,

T.

Rowe

Price

Group,

Inc.;

Chair

of

the

Board,

Chief

Executive

Officer,

President,

and

Secretary,

T.

Rowe

Price

Trust

Company;

Principal

Executive

Officer

and

Executive

Vice

President,

all

funds

Robert

W.

Sharps,

CFA,

CPA

(b)

(1971)

2017

[0]

Director

and

Vice

President,

T.

Rowe

Price;

Director,

Price

Investment

Management;

Chief

Executive

Officer

and

President,

T.

Rowe

Price

Group,

Inc.;

Vice

President,

T.

Rowe

Price

Trust

Company

INDEPENDENT

DIRECTORS

(a)

(CONTINUED)

T.

ROWE

PRICE

Health

Sciences

Fund

56

OFFICERS

Name

(Year

of

Birth)

Year

Elected

[Number

of

T.

Rowe

Price

Portfolios

Overseen]

Principal

Occupation(s)

and

Directorships

of

Public

Companies

and

Other

Investment

Companies

During

the

Past

Five

Years

Eric

L.

Veiel,

CFA

(1972)

2022

[205]

Director

and

Vice

President,

T.

Rowe

Price;

Vice

President,

T.

Rowe

Price

Group,

Inc.,

and

T.

Rowe

Price

Trust

Company

(a)

All

information

about

the

interested

directors

was

current

as

of

January

1,

2022,

unless

otherwise

indicated,

except

for

the

number

of

portfolios

overseen,

which

is

current

as

of

the

date

of

this

report.

(b)

Effective

February

3,

2022,

Mr.

Sharps

resigned

from

his

role

as

an

interested

director

of

the

Price

Funds.

Name

(Year

of

Birth)

Position

Held

With

Health

Sciences

Fund

Principal

Occupation(s) 

Zachary

Baca 

(1990)

Vice

President

Vice

President,

T.

Rowe

Price;

formerly,

Associate,

Rock

Springs

Capital

(to

2020)

Ziad

Bakri,

M.D.,

CFA

(1980)

President

Vice

President,

T.

Rowe

Price

and

T.

Rowe

Price

Group,

Inc.

Armando

(Dino)

Capasso

(1974)

Chief

Compliance

Officer

Chief

Compliance

Officer

and

Vice

President,

T.

Rowe

Price

and

Price

Investment

Management;

Vice

President,

T.

Rowe

Price

Group,

Inc.;

formerly,

Chief

Compliance

Officer,

PGIM

Investments

LLC

and

AST

Investment

Services,

Inc.

(ASTIS)

(to

2022);

Chief

Compliance

Officer,

PGIM

Retail

Funds

complex

and

Prudential

Insurance

Funds

(to

2022);

Vice

President

and

Deputy

Chief

Compliance

Officer,

PGIM

Investments

LLC

and

ASTIS

(to

2019);

Senior

Vice

President

and

Senior

Counsel,

Pacific

Investment

Management

Company

LLC

(to

2017) 

Anne

Daub

(1973)

Vice

President

Vice

President,

T.

Rowe

Price

and

T.

Rowe

Price

Group,

Inc.;

formerly,

Senior

Analyst,

Soros

Fund

Management

LLC

(to

2018)

Alan

S.

Dupski,

CPA

(1982)

Principal

Financial

Officer,

Vice

President,

and

Treasurer

Vice

President,

Price

Investment

Management,

T.

Rowe

Price,

T.

Rowe

Price

Group,

Inc.,

and

T.

Rowe

Price

Trust

Company

Unless

otherwise

noted,

officers

have

been

employees

of

T.

Rowe

Price

or

Price

International

for

at

least

5

years.

INTERESTED  DIRECTORS

(a)

(CONTINUED)

T.

ROWE

PRICE

Health

Sciences

Fund

57

Name

(Year

of

Birth)

Position

Held

With

Health

Sciences

Fund

Principal

Occupation(s) 

Gary

J.

Greb

(1961)

Vice

President

Vice

President,

Price

Investment

Management,

T.

Rowe

Price,

Price

International,

and

T.

Rowe

Price

Trust

Company

John

Hall

(1977)

Vice

President

Vice

President,

T.

Rowe

Price

and

T.

Rowe

Price

Group,

Inc.

Cheryl

Hampton,

CPA

(1969)

Vice

President

Vice

President,

T.

Rowe

Price;

formerly,

Tax

Director,

Invesco

Ltd.

(to

2021);

Vice

President,

Oppenheimer

Funds,

Inc.

(to

2019)

Amanda

Ho 

(1993)

Vice

President

Employee,

T.

Rowe

Price;

summer

intern,

T.

Rowe

Price

(to

2020);

formerly,

Revenue

Strategy,

Senior

Analyst,

Snap,

Inc.

(to

2019)

Kate

Hobbs

(1982)

Vice

President

Vice

President,

T.

Rowe

Price

and

T.

Rowe

Price

Group,

Inc.;

formerly,

Portfolio

Manager,

Millennium

Partners

(to

2020);

Senior

Analyst,

Citadel

LLC,

Aptigon

Capital

(to

2018)

Jeffrey

Holford,

Ph.D.,

ACA

(1972)

Vice

President

Vice

President,

T.

Rowe

Price

and

T.

Rowe

Price

Group,

Inc.;

formerly,

Managing

Director,

Jeffries

Financial

Group

(to

2018)

Rachel

D.

Jonas

(1983)

Vice

President

Vice

President,

T.

Rowe

Price

and

T.

Rowe

Price

Group,

Inc.

Jill

Jortner

(1977)

Vice

President

Employee,

T.

Rowe

Price;

formerly,

Research

Analyst,

Iridian

Asset

Management

(to

2022)

Benjamin

Kersse,

CPA

(1989)

Vice

President

Vice

President,

T.

Rowe

Price

Paul

J.

Krug,

CPA

(1964)

Vice

President

Vice

President,

T.

Rowe

Price,

T.

Rowe

Price

Group,

Inc.,

and

T.

Rowe

Price

Trust

Company

Fran

M.

Pollack-Matz

(1961)

Vice

President

and

Secretary 

Vice

President,

T.

Rowe

Price,

T.

Rowe

Price

Group,

Inc.,

T.

Rowe

Price

Investment

Services,

Inc.,

and

T.

Rowe

Price

Services,

Inc.

Shannon

H.

Rauser

(1987)

Assistant

Secretary 

Assistant

Vice

President,

T.

Rowe

Price

Taymour

R.

Tamaddon,

CFA

(1976)

Vice

President

Vice

President,

T.

Rowe

Price,

T.

Rowe

Price

Group,

Inc.,

and

T.

Rowe

Price

Trust

Company

Unless

otherwise

noted,

officers

have

been

employees

of

T.

Rowe

Price

or

Price

International

for

at

least

5

years.

OFFICERS

(CONTINUED)

T.

ROWE

PRICE

Health

Sciences

Fund

58

Name

(Year

of

Birth)

Position

Held

With

Health

Sciences

Fund

Principal

Occupation(s) 

Megan

Warren

(1968)

Vice

President

OFAC

Sanctions

Compliance

Officer

and

Vice

President,

Price

Investment

Management;

Vice

President,

T.

Rowe

Price,

T.

Rowe

Price

Group,

Inc.,

T.

Rowe

Price

Retirement

Plan

Services,

Inc.,

T.

Rowe

Price

Services,

Inc.,

and

T.

Rowe

Price

Trust

Company

Unless

otherwise

noted,

officers

have

been

employees

of

T.

Rowe

Price

or

Price

International

for

at

least

5

years.

OFFICERS

(CONTINUED)

T.

Rowe

Price

Investment

Services,

Inc.

|

100

East

Pratt

Street

|

Baltimore,

MD

21202-1009

You

have

many

investment

goals.

Explore

products

and

services

that

can

help

you

achieve

them.

Whether

you

want

to

put

away

more

money

for

retirement,

for

a

child’s

education,

or

for

other

priorities,

we

have

solutions

for

you.

See

how

we

can

help

you

accomplish

the

investment

goals

that

are

important

to

you.

RETIREMENT

IRAs:

Traditional,

Roth,

Rollover/Transfer,

or

Brokerage

Small

Business

Plans

help

minimize

taxes,

maximize

savings

T.

Rowe

Price

®

ActivePlus

Portfolios

1

for

online

investing

powered

by

experts

GENERAL

INVESTING

Individual

or

Joint

Tenant

Brokerage

2

offers

access

to

stocks,

ETFs,

bonds,

and

more

Gifts

and

transfers

to

a

child

(UGMA/UTMAs)

Trust

Transfer

on

Death

COLLEGE

SAVINGS

T.

Rowe

Price-managed

529

plans

offer

tax-

advantaged

solutions

for

families

saving

money

for

college

tuition

and

education-

related

expenses

Visit

troweprice.com/broadrange

Call

1-800-225-5132

to

request

a

prospectus

or

summary

prospectus;

each

includes

investment

objectives,

risks,

fees,

expenses,

and

other

information

that

you

should

read

and

consider

carefully

before

investing.

All

mutual

funds

are

subject

to

market

risk,

including

possible

loss

of

principal.

Investing

internationally

involves

special

risks

including

economic

and

political

uncertainty

and

currency

fluctuation.

1

The

T.

Rowe

Price

®

ActivePlus

Portfolios

is

a

discretionary

investment

management

program

provided

by

T.

Rowe

Price

Advisory

Services,

Inc.,

a

registered

investment

adviser

under

the

Investment

Advisers

Act

of

1940.

Brokerage

services

are

provided

by

T.

Rowe

Price

Investment

Services,

Inc.,

member

FINRA/SIPC.

Brokerage

accounts

are

carried

by

Pershing

LLC,

a

BNY

Mellon

Company,

member

NYSE/FINRA/SIPC.

T.

Rowe

Price

Advisory

Services,

Inc.,

and

T.

Rowe

Price

Investment

Services,

Inc.,

are

affiliated

companies.

2

Brokerage

services

are

provided

by

T.

Rowe

Price

Investment

Services,

Inc.,

member

FINRA/SIPC.

Brokerage

accounts

are

carried

by

Pershing

LLC,

a

BNY

Mellon

Company,

member

NYSE/FINRA/SIPC.

202302-2582632

F114-050

2/23

Item 1. (b) Notice pursuant to Rule 30e-3.

Not applicable.

Item 2.  Code of Ethics.

The registrant has adopted a code of ethics, as defined in Item 2 of Form N-CSR, applicable to its principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A copy of this code of ethics is filed as an exhibit to this Form N-CSR. No substantive amendments were approved or waivers were granted to this code of ethics during the period covered by this report.

Item 3.  Audit Committee Financial Expert.

The registrant’s Board of Directors has determined that Ms. Teresa Bryce Bazemore qualifies as an audit committee financial expert, as defined in Item 3 of Form N-CSR. Ms. Bazemore is considered independent for purposes of Item 3 of Form N-CSR.

Item 4.  Principal Accountant Fees and Services.

(a) – (d)  Aggregate fees billed for the last two fiscal years for professional services rendered to, or on behalf of, the registrant by the registrant’s principal accountant were as follows:

	2022		2021
Audit Fees	$	41,909	$	40,759
Audit-Related Fees		-		-
Tax Fees		-		5,742
All Other Fees		-		-

Audit fees include amounts related to the audit of the registrant’s annual financial statements and services normally provided by the accountant in connection with statutory and regulatory filings. Audit-related fees include amounts reasonably related to the performance of the audit of the registrant’s financial statements and specifically include the issuance of a report on internal controls and, if applicable, agreed-upon procedures related to fund acquisitions. Tax fees include amounts related to services for tax compliance, tax planning, and tax advice. The nature of these services specifically includes the review of distribution calculations and the preparation of Federal, state, and excise tax returns. All other fees include the registrant’s pro-rata share of amounts for agreed-upon procedures in conjunction with service contract approvals by the registrant’s Board of Directors/Trustees.

(e)(1)  The registrant’s audit committee has adopted a policy whereby audit and non-audit services performed by the registrant’s principal accountant for the registrant, its investment adviser, and any entity controlling, controlled by, or under common control with the investment adviser that provides ongoing services to the registrant require pre-approval in advance at regularly scheduled audit committee meetings. If such a service is required between regularly scheduled audit committee meetings, pre-approval may be authorized by one audit committee member with ratification at the next scheduled audit committee meeting. Waiver of pre-approval for audit or non-audit services requiring fees of a de minimis amount is not permitted.

(2)  No services included in (b) – (d) above were approved pursuant to paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X.

(f)  Less than 50 percent of the hours expended on the principal accountant’s engagement to audit the registrant’s financial statements for the most recent fiscal year were attributed to work performed by persons other than the principal accountant’s full-time, permanent employees.

(g)  The aggregate fees billed for the most recent fiscal year and the preceding fiscal year by the registrant’s principal accountant for non-audit services rendered to the registrant, its investment adviser, and any entity controlling, controlled by, or under common control with the investment adviser that provides ongoing services to the registrant were $2,037,000 and $3,732,000, respectively.

(h)  All non-audit services rendered in (g) above were pre-approved by the registrant’s audit committee. Accordingly, these services were considered by the registrant’s audit committee in maintaining the principal accountant’s independence.

Item 5.  Audit Committee of Listed Registrants.

Not applicable.

Item 6. Investments.

(a)  Not applicable. The complete schedule of investments is included in Item 1 of this Form N-CSR.

(b)  Not applicable.

Item 7.  Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.

Not applicable.

Item 8.  Portfolio Managers of Closed-End Management Investment Companies.

Not applicable.

Item 9.  Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.

Not applicable.

Item 10.  Submission of Matters to a Vote of Security Holders.

There has been no change to the procedures by which shareholders may recommend nominees to the registrant’s board of directors.

Item 11.  Controls and Procedures.

(a)  The registrant’s principal executive officer and principal financial officer have evaluated the registrant’s disclosure controls and procedures within 90 days of this filing and have concluded that the registrant’s disclosure controls and procedures were effective, as of that date, in ensuring that information required to be disclosed by the registrant in this Form N-CSR was recorded, processed, summarized, and reported timely.

(b)  The registrant’s principal executive officer and principal financial officer are aware of no change in the registrant’s internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

Item 12. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.

Not applicable.

Item 13.   Exhibits.

(a)(1) The registrant’s code of ethics pursuant to Item 2 of Form N-CSR is attached.

    (2) Separate certifications by the registrant’s principal executive officer and principal financial officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and required by Rule 30a-2(a) under the Investment Company Act of 1940, are attached.

    (3) Written solicitation to repurchase securities issued by closed-end companies: not applicable.

(b) A certification by the registrant’s principal executive officer and principal financial officer, pursuant to Section  906 of the Sarbanes-Oxley Act of 2002 and required by Rule 30a-2(b) under the Investment Company Act of 1940, is attached.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

T. Rowe Price Health Sciences Fund, Inc.

By	/s/ David Oestreicher
	David Oestreicher
	Principal Executive Officer
Date	February 16, 2023

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By	/s/ David Oestreicher
	David Oestreicher
	Principal Executive Officer
Date	February 16, 2023

By	/s/ Alan S. Dupski
	Alan S. Dupski
	Principal Financial Officer
Date	February 16, 2023